

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199711263 B2
(10) Patent No. 722042

(54) Title
Methods and compositions for the diagnosis and treatment of cancer

(51)⁷ International Patent Classification(s)
C12N 015/12 A61K 048/00

(21) Application No: **199711263**

(22) Application Date: **1996.11.27**

(87) WIPO No: **WO97/20047**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/007810	1995.11.30	US

(43) Publication Date : **1997.06.19**

(43) Publication Journal Date : **1997.08.14**

(44) Accepted Journal Date : **2000.07.20**

(71) Applicant(s)
Board of Regents, The University of Texas System

(72) Inventor(s)
Gary L. Clayman

(74) Agent/Attorney
DAVIES COLLISON CAVE, 1 Little Collins Street, MELBOURNE VIC 3000

(56) Related Art
CANCER RESEARCH, VOL 54, 1994, 3662-3667
CANCER RESEARCH, VOL 55, 1995, 3117-3122
CANCER RESEARCH, VOL 55, 1995, 1-6

OPI DATE 19/06/97 APPLN. ID 11263/97
AOJP DATE 14/08/97 PCT NUMBER PCT/US96/19083



AU9711263

(51) International Patent Classification ^o :
C12N 15/12, A61K 48/00

A1

(11) International Publication Number:

WO 97/20047

(43) International Publication Date:

5 June 1997 (05.06.97)

(21) International Application Number: PCT/US96/19083

(22) International Filing Date: 27 November 1996 (27.11.96)

(30) Priority Data:
60/007,810 30 November 1995 (30.11.95) US

(60) Parent Application or Grant
(63) Related by Continuation
US 60/007,810 (CIP)
Filed on 30 November 1995 (30.11.95)

(71) Applicant (for all designated States except US): BOARD
OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
[US/US]; 201 West 7th Street, Austin, TX 78701 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): CLAYMAN, Gary, L.
[US/US]; 6353 Westchester, Houston, TX 77005 (US).

(74) Agent: HIGHLANDER, Steven, L.; Arnold, White & Durkee,
P.O. Box 4433, Houston, TX 77210 (US).

(81) Designated States: AL, AM, AT, AU, BA, BB, BG, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER

(57) Abstract

Methods for the treatment of squamous cell carcinoma using a p53-expressing viral vector are disclosed. In particular embodiments, the vector is a replication-deficient adenovirus. In addition, there are provided methods for examining the development and treatment of microscopic residual disease in the context of post-surgical environments and in body cavities.



-1-

DESCRIPTION**METHODS AND COMPOSITIONS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER**

5

BACKGROUND OF THE INVENTION

The present application is a continuation-in-part of U.S. Provisional Patent Application Serial No. 60/007,810 filed November 30, 1995. The entire text of the
10 above-referenced disclosure is specifically incorporated by reference herein without disclaimer

A. Field of the Invention

15 The present invention is related generally to the field of cancer biology. In particular, the invention relates to compositions and methods of treatment for squamous cell carcinoma. Also provided is an animal model for the examination of microscopic residual tumors and tumor seeding into body cavities, as well as methods for treatment thereof.

20

B. Related Art

Balancing rates of cell proliferation and cell death is important in maintaining normal tissue homeostasis. Disruption of this balance may be a major factor in the
25 multistep process of tumorigenesis, and inhibition of apoptosis, or programmed cell death, is one cause of this disruption. The effects of such defects are catastrophic, causing over half a million deaths annually in the United States alone.

-2-

There is considerable evidence implicating mutations of the *p53* gene, a tumor suppressor, in the etiology of many human cancers. Reports have demonstrated that growth of several different human cancer cell lines, including representatives of colon cancer, glioblastoma, breast cancer, osteosarcoma and lung cancer can be functionally suppressed by viral-mediated transfer of a wild-type *p53* gene. Induction of exogenous *p53* expression of wild-type *p53* has been shown to induce apoptosis in colon cancer cell lines and in human lung cancer spheroids, suggesting a role for *p53* in programmed cell death.

Patients with squamous cell carcinoma of the head and neck (SCCHN) are afflicted with a disease that often has profound effects on speech, swallowing and cosmesis. Moreover, the overall rate of survival among these patients, approximately 50%, has remained unchanged for the nearly 30 years since contemporary surgery and radiation therapy were instituted. Recurrences are predominantly local and regional as opposed to systemic, indicating that microscopic residual carcinoma at the primary tumor site are the main cause of mortality. Given these facts, the ability to effectively attack microscopic residual disease in SCCHN is an endeavor that could improve the therapeutic efficacy of cancer treatments.

SUMMARY OF THE INVENTION

Therefore, it is an object of the present invention to provide improved methods for the *in vivo* treatment of squamous cell carcinoma. It is another object of the present invention to provide a method for assessing the development and treatment of microscopic residual carcinoma and microscopic tumor seeding of body cavities.

In fulfilling these objects, there is provided a method for treating a subject with squamous cell carcinoma comprising the steps of (a) providing an expression construct comprising a promoter functional in eukaryotic cells and a polynucleotide

-3-

encoding a *p53*, wherein the polynucleotide is positioned sense to and under the control of the promoter; and (b) contacting the expression construct with the squamous cell carcinoma *in vivo*.

5 The squamous cell carcinoma may be a head and neck carcinoma. The endogenous *p53* of the squamous cell carcinoma may or may not be mutated. The expression construct preferably is a viral vector, such as a retroviral vector, an adenoviral vector and an adeno-associated viral vector, with a replication-deficient adenoviral vector being most preferred. In a particular embodiment, the *p53* gene is
10 tagged so that expression of *p53* from the expression vector can be detected. A preferred tag is an immunologic one, such as a continuous antibody epitope.

 The method may further comprise surgical resection of the tumor, with additional contacting of the tumor bed, or "artificial body cavity," with the expression
15 construct after resection. The volume used to contact the tumor bed is about 3 ml. to about 10 ml. Where an adenovirus vector is employed, the amount of adenovirus administered in each contacting is about 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} or 10^{12} pfu.

 Continuous perfusion of the expression construct also is contemplated. The
20 amount of construct delivered in continuous perfusion will be determined from the amount delivered via injections so as to approximate the same total dosage over a given time period, although somewhat greater total dosages may be achieved using continuous perfusion.

25 In another embodiment, the expression construct is injected into an natural body cavity such as the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, or hollow organ cavities including the bladder, colon or other visceral organs.

-4-

Also provided is a method for determining the effectiveness of a therapy on microscopic residual cancer comprising (a) providing a rodent with an incision into subcutaneous tissue; (b) seeding the incision with tumor cells; (c) treating the rodent with a therapeutic regimen; and (d) assessing the impact of the regimen on the development of tumors. The incision may be sealed following step (b) and prior to step (c). Further, the regimen may comprise introduction of a therapeutic composition into the incision, the incision being reopened after sealing and resealed after introduction of said therapeutic composition.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein:

FIG. 1. Transduction efficiency of SCCHN cell lines Tu-138 (closed triangles) and Tu177 (closed squares). A recombinant β -gal adenovirus was used to infect the cells at different MOI ranging from 10 to 100. The percentages of β -gal-positive cells were obtained from scoring 500 cells each on replicate dishes.

FIG. 2A and FIG. 2B. Inhibition of SCCHN cell growth *in vitro*. (**FIG. 2A**) Growth curve of mock-infected Tu-138 cells (closed circles), dl312-infected cells (closed triangles), and Ad5CMV-*p53*-infected cells (closed squares). (**FIG. 2B**) Growth curve of mock-infected Tu-177 cells (open circles), dl312-infected cells (open triangles), and Ad5CMV-*p53*-infected cells (open squares). At each indicated time point, three dishes of cells were trypsinized and counted. The mean \pm SEM of cell counts per triplicate wells following infection were plotted against the number of days since infection.

FIG. 3A, FIG. 3B, FIG. 3C and FIG. 3D. Composite Growth Curve of four SCCHN cell lines. (**FIG. 3A**) Tu-138. (**FIG. 3B**) Tu-177. (**FIG. 3C**) MDA 686-LN. (**FIG. 3D**) MDA 886. Mock infected cells (closed circles), dl312-infected cells (closed triangle), and Ad5CMV-*p53* infected cells (closed square). The mean of cell counts per triplicate wells following infection were plotted against the number of days since infection; bars, SEM.

FIG. 4. Growth curve of normal fibroblast cell line. Mock-infected cells (closed circle), dl312-infected cells (closed triangle), and Ad5CMV-*p53*-infected cells (closed square).

FIG. 5A and FIG. 5B. Composite growth curve of SCCHN cell lines. **FIG. 5A:** Tu-138; **FIG. 5B:** MDA 686LN; Mock infected cells (open square), dl312 infected cells (open triangle), and Ad5CMV-*p53* infected cells (open circle). At each indicated time point, three dishes of cells were trypsinized and counted. The mean of cell counts per triplicate dishes were plotted against the number of hours post-infection; bars, SEM.

FIG. 6A and FIG. 6B. Labeling of DNA breaks in apoptotic cells with biotinylated-dUTP by TUNEL method. Following infection, flow cytometric analysis

-6-

for apoptosis was performed in a time course study. **FIG. 6A.** Tu-138 cells which are infected with dl312, a replication-defective adenovirus (panel 1-panel 4), Tu-138 cells infected with the wild-type *p53* adenovirus (panel 5- panel 8). **FIG. 6B.** MDA 686LN cells which are infected with dl312, a replication-defective adenovirus (A-D),
5 MDA 686LN cells infected with the wild-type *p53* adenovirus (E-H). Ap stands for apoptosis.

FIG. 7A and FIG. 7B. Composite growth curve of SCCHN cell line. **FIG. 7A:** Tu-138; **FIG. 7B:** MD686LN; Mock infected cells (open circles), dl312
10 infected cells (closed triangles), Ad5CMV-*p53* infected cells (open squares) and Ad5CMV-*p53*-FLAG infected cells (closed squares). At each indicated time point, three dishes of cells were trypsinized and counted. The mean of cell counts per triplicate dishes were plotted against the number of hours post-infection; *bars*, SEM.

15 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Information available to date suggests that one of the primary shortcomings of treatments for SCCHN is the inability to completely eradicate disease at the primary tumor site, or in the immediate local or regional tissues. Therefore, the present
20 invention is designed to provide gene therapeutic methodologies that permit a more complete and effective treatment of SCCHN, specifically, by attacking microscopic residual carcinoma. This methodology may be used alone or as an adjunct to more conventional treatments such as chemo- or radiotherapy or surgical intervention. Moreover, using an animal model specifically designed to address microscopic
25 residual carcinoma, as well as microscopic tumor seeding of body cavities, the present inventor has demonstrated efficacy of these methods. The details of the invention are described more completely below.

-7-

More generally, it now has been observed that p53 gene therapy of cancers may be effective regardless of the p53 status of the tumor cell. Surprisingly, therapeutic effects have been observed when a viral vector carrying the wild-type p53 gene is used to treat a tumor, the cells of which express a functional p53 molecule.

5 This result would not have been predicted based on the current understanding of how tumor suppressors function. It also is surprising given that normal cells, which also express a functional p53 molecule, are apparently unaffected by expression of high levels of p53 from a viral construct. This raises the possibility that p53 gene therapy may be more broadly applicable to the treatment of cancers than was initially

10 suspected.

A. *p53* Proteins and Polynucleotides

Throughout this application, the term "*p53*" is intended to refer to the exemplified *p53* molecules as well as all *p53* homologues from other species. "Wild-type" and "mutant" *p53* refer, respectively, to a *p53* gene expressing normal tumor suppressor activity and to a *p53* gene lacking or having reduced suppressor activity and/or having transforming activity. Thus "mutant" *p53*'s are not merely sequence variants but rather, are those variants showing altered functional profiles.

15

20

p53 is currently recognized as a tumor suppressor gene (Montenarh, 1992). High levels have been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses, including SV40. The *p53* gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already

25 documented to be the most frequently-mutated gene in common human cancers (Mercer, 1992). It is mutated in over 50% of human NSCLC (Hollestein *et al.*, 1991) and in a wide spectrum of other tumors.

-8-

While tumors containing a mutated *p53* gene are a preferred target according to the present invention, the utility of the claimed *p53* expression vectors extends to the treatment of tumors having wild-type or functional *p53*. Though the mechanism is not completely understood, the present inventor has determined that *p53* expression
5 can limit the growth of tumors expressing a functional *p53* product, and even induce apoptosis in such cells. Thus, the *p53* status of a tumor, though potentially useful in a diagnostic context, is not essential for practice of the present invention. This phenomenon is not limited to SCCHN tumors, but may be applied to a wide variety of malignancies including gliomas, sarcomas, carcinomas, leukemias, lymphomas and
10 melanoma, including tumors of the skin, liver, testes, bone, brain, pancreas, head and neck, stomach, liver, lung, ovary, breast, colon, prostate and bladder.

p53 Polypeptides

The *p53* gene encodes a 375-amino-acid phosphoprotein that can form
15 complexes with viral proteins such as large-T antigen and E1B. The protein is found in normal tissues and cells, but at concentrations which are minute by comparison with many transformed cells or tumor tissue. Interestingly, wild-type *p53* appears to be important in regulating cell growth and division. Overexpression of wild-type *p53* has been shown in some cases to be anti-proliferative in human tumor cell lines. Thus
20 *p53* can act as a negative regulator of cell growth (Weinberg, 1991) and may directly suppress uncontrolled cell growth or indirectly activate genes that suppress this growth. Thus, absence or inactivation of wild-type *p53* may contribute to transformation. However, some studies indicate that the presence of mutant *p53* may be necessary for full expression of the transforming potential of the gene.

25

Although wild-type *p53* is recognized as a centrally important growth regulator in many cell types, its genetic and biochemical traits appear to have a role as well. Mis-sense mutations are common for the *p53* gene and are essential for the transforming ability of the oncogene. A single genetic change prompted by a point

-9-

mutation can create carcinogenic *p53*. Unlike other oncogenes, however, *p53* point mutations are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity. Additionally, many of these dominant negative alleles appear to be tolerated in the
5 organism and passed on in the germ line. Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Weinberg, 1991).

Casey and colleagues have reported that transfection of DNA encoding
10 wild-type *p53* into two human breast cancer cell lines restores growth suppression control in such cells (Casey *et al.*, 1991). A similar effect has also been demonstrated on transfection of wild-type, but not mutant, *p53* into human lung cancer cell lines (Takahasi *et al.*, 1992). The *p53* wild-type appears dominant over the mutant gene and will select against proliferation when transfected into cells with the mutant gene.
15 Expression of the transfected *p53* does not affect the growth of normal cells with endogenous *p53*. Thus, such constructs might be taken up by normal cells without adverse effects.

It is thus possible that the treatment of *p53*-associated cancers with wild-type
20 *p53* may reduce the number of malignant cells. However, studies such as those described above are far from achieving such a goal, not least because DNA transfection cannot be employed to introduce DNA into cancer cells within a patients' body.

25 ***p53*-Encoding Polynucleotides**

The polynucleotides according to the present invention may encode an entire *p53* gene, a functional *p53* protein domain, or any *p53* polypeptide. "Complementary" polynucleotides are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules. That is, the larger

-10-

purines will base pair with the smaller pyrimidines to form combinations of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. Inclusion of less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and
5 others in hybridizing sequences does not interfere with pairing.

As used herein, the term "complementary sequences" means polynucleotide sequences that are substantially complementary over their entire length and have very few base mismatches. For example, sequences of fifteen bases in length may be
10 termed complementary when they have a complementary nucleotide at thirteen or fourteen positions. Naturally, sequences which are "completely complementary" will be sequences which are entirely complementary throughout their entire length and have no base mismatches.

15 Other sequences with lower degrees of homology also are contemplated. For example, an antisense construct which has limited regions of high homology, but also contains a non-homologous region (*e.g.*, a ribozyme) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.

20 The polynucleotides may be derived from genomic DNA, *i.e.*, cloned directly from the genome of a particular organism. In other embodiments, however, the polynucleotides may be complementary DNA (cDNA). cDNA is DNA prepared using messenger RNA (mRNA) as template. Thus, a cDNA does not contain any
25 interrupted coding sequences and usually contains almost exclusively the coding region(s) for the corresponding protein. In other embodiments, the polynucleotide may be produced synthetically.

-11-

It may be advantageous to combine portions of the genomic DNA with cDNA or synthetic sequences to generate specific constructs. For example, where an intron is desired in the ultimate construct, a genomic clone will need to be used. Introns may be derived from other genes in addition to *p53*. The cDNA or a synthesized polynucleotide may provide more convenient restriction sites for the remaining portion of the construct and, therefore, would be used for the rest of the sequence.

The human and mouse DNA sequence for *p53* is provided in SEQ ID NO:1 and SEQ ID NO:3 respectively, with the corresponding amino acids being provided in SEQ ID NO:2 and SEQ ID NO:4, respectively.

It is contemplated that natural variants of *p53* exist that have different sequences than those disclosed herein. Thus, the present invention is not limited to use of the provided polynucleotide sequence for *p53* but, rather, includes use of any naturally-occurring variants. The present invention also encompasses chemically synthesized mutants of these sequences.

Another kind of sequence variant results from codon variation. Because there are several codons for most of the 20 normal amino acids, many different DNA's can encode the *p53*. Reference to the following table will allow such variants to be identified.

-12-

TABLE 1

Amino Acids		Codons							
Alanine	Ala	A	GCA	GCC	GCG	GCU			
Cysteine	Cys	C	UGC	UGU					
Aspartic acid	Asp	D	GAC	GAU					
Glutamic acid	Glu	E	GAA	GAG					
Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU	
Threonine	Thr	T	ACA	ACC	ACG	ACU			
Valine	Val	V	GUA	GUC	GUG	GUU			
Tryptophan	Trp	W	UGG						
Tyrosine	Tyr	Y	UAC	UAU					

5 Allowing for the degeneracy of the genetic code, sequences that have between about 50% and about 75%, or between about 76% and about 99% of nucleotides that are identical to the nucleotides disclosed herein will be preferred. Sequences that are within the scope of "a *p53*-encoding polynucleotide" are those that are capable of base-pairing with a polynucleotide segment set forth above under intracellular conditions.

-13-

As stated above, although the *p53* encoding sequences may be full length genomic or cDNA copies, or large fragments thereof. The present invention also may employ shorter oligonucleotides of *p53*. Sequences of 17 bases long should occur
5 only once in the human genome and, therefore, suffice to specify a unique target sequence. Although shorter oligomers are easier to make and increase *in vivo* accessibility, numerous other factors are involved in determining the specificity of base-pairing. Both binding affinity and sequence specificity of an oligonucleotide to its complementary target increases with increasing length. It is contemplated that
10 oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 base pairs will be used, for example, in the preparation of *p53* mutants and in PCR reactions.

Any sequence of 17 bases long should occur only once in the human genome and, therefore, suffice to specify a unique target sequence. Although shorter
15 oligomers are easier to make and increase *in vivo* accessibility, numerous other factors are involved in determining the specificity of hybridization. Both binding affinity and sequence specificity of an oligonucleotide to its complementary target increases with increasing length.

20 In certain embodiments, one may wish to employ constructs which include other elements, for example, those which include C-5 propyne pyrimidines. Oligonucleotides which contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity (Wagner *et al.*, 1993).

25 It also is well understood by the skilled artisan that, inherent in the definition of a biologically functional equivalent protein or peptide, is the concept that there is a limit to the number of changes that may be made within a defined portion of the molecule and still result in a molecule with an acceptable level of equivalent biological activity. Biologically functional equivalent peptides are thus defined herein as those

-14-

peptides in which certain, not most or all, of the amino acids may be substituted. In particular, where the N-terminus of the p16 protein is concerned, it is contemplated that only about 16 or more preferably, about 5 amino acids may be changed within a given peptide. Of course, a plurality of distinct proteins/peptides with different
5 substitutions may easily be made and used in accordance with the invention.

Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. An analysis of the size, shape and type of the amino acid
10 side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as biologically
15 functional equivalents.

In making changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine
20 (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

25 The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte & Doolittle, 1982, incorporated herein by reference). It is known that ceratin amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic

-15-

index, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

5 It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent protein. As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2);
10 glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

 In making changes based upon similar hydrophilicity values, the substitution
15 of amino acids whose hydrophilicity values are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

20 B. Expression Vectors

 Throughout this application, the term "expression construct" is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. Thus,
25 in certain embodiments, expression includes both transcription of a *p53* gene and translation of a *p53* mRNA into a *p53* protein product. In other embodiments, expression only includes transcription of the nucleic acid encoding a *p53* or its complement.

-16-

In order for the construct to effect expression of at least a *p53* transcript, the polynucleotide encoding the *p53* polynucleotide will be under the transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the host cell, or introduced synthetic machinery, that is
5 required to initiate the specific transcription of a gene. The phrase "under transcriptional control" means that the promoter is in the correct location in relation to the polynucleotide to control RNA polymerase initiation and expression of the polynucleotide.

10 The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown
15 that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.

At least one module in each promoter functions to position the start site for
20 RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.

25 Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements

-17-

are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

5

The particular promoter that is employed to control the expression of a *p53* polynucleotide is not believed to be critical, so long as it is capable of expressing the polynucleotide in the targeted cell at sufficient levels. Thus, where a human cell is targeted, it is preferable to position the polynucleotide coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a human or viral promoter.

10

In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can be used to obtain high-level expression of the *p53* polynucleotide. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of polynucleotides is contemplated as well, provided that the levels of expression are sufficient to produce a growth inhibitory effect.

15

20

By employing a promoter with well-known properties, the level and pattern of expression of a polynucleotide following transfection can be optimized. For example, selection of a promoter which is active in specific cells, such as tyrosinase (melanoma), alpha-fetoprotein and albumin (liver tumors), CC10 (lung tumor) and prostate-specific antigen (prostate tumor) will permit tissue-specific expression of *p53* polynucleotides. Table 2 lists several elements/promoters which may be employed, in the context of the present invention, to regulate the expression of *p53* constructs. This list is not intended to be exhaustive of all the possible elements involved in the promotion of *p53* expression but, merely, to be exemplary thereof.

25

Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.

The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.

Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of a *p53* construct. Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacteriophage promoters if the appropriate bacteriophage polymerase is provided, either as part of the delivery complex or as an additional genetic expression vector.

TABLE 2

ENHANCER
Immunoglobulin Heavy Chain
Immunoglobulin Light Chain
T-Cell Receptor
HLA DQ α and DQ β
β -Interferon
Interleukin-2
Interleukin-2 Receptor
MHC Class II 5
MHC Class II HLA-DR α
β -Actin
Muscle Creatine Kinase
Prealbumin (Transthyretin)
Elastase <i>I</i>
Metallothionein
Collagenase
Albumin Gene
α -Fetoprotein
τ -Globin
β -Globin
c-fos
c-HA-ras
Insulin
Neural Cell Adhesion Molecule (NCAM)
α_1 -Antitrypsin
H2B (TH2B) Histone
Mouse or Type I Collagen

Table 2 cont'd

ENHANCER
Glucose-Regulated Proteins (GRP94 and GRP78)
Rat Growth Hormone
Human Serum Amyloid A (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor
Duchenne Muscular Dystrophy
SV40
Polyoma
Retroviruses
Papilloma Virus
Hepatitis B Virus
Human Immunodeficiency Virus
Cytomegalovirus
Gibbon Ape Leukemia Virus

Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the *p53* construct. For example, with the polynucleotide under the control of the human PAI-1 promoter, expression is

5 inducible by tumor necrosis factor. Table 3 illustrates several promoter/inducer combinations:

TABLE 3

Element	Inducer
MT II	Phorbol Ester (TFA) Heavy metals
MMTV (mouse mammary tumor virus)	Glucocorticoids
β -Interferon	poly(rI)X poly(rc)
Adenovirus 5 E2	Ela
c-jun	Phorbol Ester (TPA), H ₂ O ₂
Collagenase	Phorbol Ester (TPA)
Stromelysin	Phorbol Ester (TPA), IL-1
SV40	Phorbol Ester (TPA)
Murine MX Gene	Interferon, Newcastle Disease Virus
GRP78 Gene	A23187
α -2-Macroglobulin	IL-6
Vimentin	Serum
MHC Class I Gene H-2kB	Interferon
HSP70	Ela, SV40 Large T Antigen
Proliferin	Phorbol Ester-TPA
Tumor Necrosis Factor	FMA
Thyroid Stimulating Hormone α Gene	Thyroid Hormone

In certain embodiments of the invention, the delivery of an expression vector in a cell may be identified *in vitro* or *in vivo* by including a marker in the expression vector. The marker would result in an identifiable change to the transfected cell permitting easy identification of expression. Usually the inclusion of a drug selection marker aids in cloning and in the selection of transformants. Alternatively, enzymes such as herpes simplex virus thymidine kinase (tk) (eukaryotic) or chloramphenicol

-22-

acetyltransferase (CAT) (prokaryotic) may be employed. Immunologic markers also can be employed. The selectable marker employed is not believed to be important, so long as it is capable of being expressed along with the polynucleotide encoding *p53*. Further examples of selectable markers are well known to one of skill in the art.

5

One typically will include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed. The inventor has employed the SV40 polyadenylation
10 signal in that it was convenient and known to function well in the target cells employed. Also contemplated as an element of the expression construct is a terminator. These elements can serve to enhance message levels and to minimize read through from the construct into other sequences.

15

In preferred embodiments of the present invention, the expression construct comprises a virus or engineered construct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis and, in some cases, integrate into the host cell chromosomes, have made them attractive candidates for gene transfer in to mammalian cells. However, because it has been demonstrated that
20 direct uptake of naked DNA, as well as receptor-mediated uptake of DNA complexes (discussed below), expression vectors need not be viral but, instead, may be any plasmid, cosmid or phage construct that is capable of supporting expression of encoded genes in mammalian cells, such as pUC or BluescriptTM plasmid series.

25

Retroviruses

The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The

-23-

integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes - *gag*, *pol*, and *env* - that code for capsid proteins, polymerase enzyme, and envelope components, respectively.

5 A sequence found upstream from the *gag* gene, termed Ψ , functions as a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990).

10 In order to construct a retroviral vector, a nucleic acid encoding a *p53* is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the *gag*, *pol* and *env* genes but without the LTR and Ψ components is constructed (Mann *et al.*, 1983). When a recombinant plasmid containing a human
15 cDNA, together with the retroviral LTR and Ψ sequences is introduced into this cell line (by calcium phosphate precipitation for example), the Ψ sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then
20 collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind *et al.*, 1975).

25 A novel approach designed to allow specific targeting of retrovirus vectors was recently developed based on the chemical modification of a retrovirus by the chemical addition of lactose residues to the viral envelope. This modification could permit the specific infection of hepatocytes via sialoglycoprotein receptors.

-24-

A different approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled via the biotin components by using streptavidin (Roux *et al.*, 1989). Using antibodies against major
5 histocompatibility complex class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus *in vitro* (Roux *et al.*, 1989).

Adenoviruses

10 Human adenoviruses are double-stranded DNA tumor viruses with genome sizes of approximate 36 kb (Tooze, 1981). As a model system for eukaryotic gene expression, adenoviruses have been widely studied and well characterized, which makes them an attractive system for development of adenovirus as a gene transfer system. This group of viruses is easy to grow and manipulate, and they exhibit a
15 broad host range *in vitro* and *in vivo*. In lytically infected cells, adenoviruses are capable of shutting off host protein synthesis, directing cellular machineries to synthesize large quantities of viral proteins, and producing copious amounts of virus.

The E1 region of the genome includes E1A and E1B which encode proteins
20 responsible for transcription regulation of the viral genome, as well as a few cellular genes. E2 expression, including E2A and E2B, allows synthesis of viral replicative functions, *e.g.* DNA-binding protein, DNA polymerase, and a terminal protein that primes replication. E3 gene products prevent cytolysis by cytotoxic T cells and tumor necrosis factor and appear to be important for viral propagation. Functions associated
25 with the E4 proteins include DNA replication, late gene expression, and host cell shutoff. The late gene products include most of the virion capsid proteins, and these are expressed only after most of the processing of a single primary transcript from the major late promoter has occurred. The major late promoter (MLP) exhibits high

efficiency during the late phase of the infection (Stratford-Perricaudet and Perricaudet, 1991a).

As only a small portion of the viral genome appears to be required *in cis*
5 (Tooze, 1981), adenovirus-derived vectors offer excellent potential for the substitution of large DNA fragments when used in connection with cell lines such as 293 cells. Ad5-transformed human embryonic kidney cell lines (Graham, *et al.*, 1977) have been developed to provide the essential viral proteins *in trans*. The inventor thus reasoned that the characteristics of adenoviruses rendered them good candidates for
10 use in targeting cancer cells *in vivo* (Grunhaus & Horwitz, 1992).

Particular advantages of an adenovirus system for delivering foreign proteins to a cell include (i) the ability to substitute relatively large pieces of viral DNA by foreign DNA; (ii) the structural stability of recombinant adenoviruses; (iii) the safety
15 of adenoviral administration to humans; and (iv) lack of any known association of adenoviral infection with cancer or malignancies; (v) the ability to obtain high titers of the recombinant virus; and (vi) the high infectivity of Adenovirus.

Further advantages of adenovirus vectors over retroviruses include the higher
20 levels of gene expression. Additionally, adenovirus replication is independent of host gene replication, unlike retroviral sequences. Because adenovirus transforming genes in the E1 region can be readily deleted and still provide efficient expression vectors, oncogenic risk from adenovirus vectors is thought to be negligible (Grunhaus & Horwitz, 1992).

25

In general, adenovirus gene transfer systems are based upon recombinant, engineered adenovirus which is rendered replication-incompetent by deletion of a portion of its genome, such as E1, and yet still retains its competency for infection. Sequences encoding relatively large foreign proteins can be expressed when additional

-26-

deletions are made in the adenovirus genome. For example, adenoviruses deleted in both E1 and E3 regions are capable of carrying up to 10 Kb of foreign DNA and can be grown to high titers in 293 cells (Stratford-Perricaudet and Perricaudet, 1991a). Surprisingly persistent expression of transgenes following adenoviral infection has
5 also been reported.

Adenovirus-mediated gene transfer has recently been investigated as a means of mediating gene transfer into eukaryotic cells and into whole animals. For example, in treating mice with the rare recessive genetic disorder ornithine transcarbamylase
10 (OTC) deficiency, it was found that adenoviral constructs could be employed to supply the normal OTC enzyme. Unfortunately, the expression of normal levels of OTC was only achieved in 4 out of 17 instances (Stratford-Perricaudet *et al.*, 1991b). Therefore, the defect was only partially corrected in most of the mice and led to no physiological or phenotypic change. These type of results therefore offer little
15 encouragement for the use of adenoviral vectors in cancer therapy.

Attempts to use adenovirus to transfer the gene for cystic fibrosis transmembrane conductance regulator (CFTR) into the pulmonary epithelium of cotton rats have also been partially successful, although it has not been possible to
20 assess the biological activity of the transferred gene in the epithelium of the animals (Rosenfeld *et al.*, 1992). Again, these studies demonstrated gene transfer and expression of the CFTR protein in lung airway cells but showed no physiologic effect. In the 1991 *Science* article, Rosenfeld *et al.* showed lung expression of α 1-antitrypsin protein but again showed no physiologic effect. In fact, they estimated that the levels
25 of expression that they observed were only about 2% of the level required for protection of the lung in humans, *i.e.*, far below that necessary for a physiologic effect.

-27-

The gene for human α 1-antitrypsin has been introduced into the liver of normal rats by intraportal injection, where it was expressed and resulted in the secretion of the introduced human protein into the plasma of these rats (Jaffe *et al.*, 1992). However, and disappointingly, the levels that were obtained were not high
5 enough to be of therapeutic value.

These type of results do not demonstrate that adenovirus is able to direct the expression of sufficient protein in recombinant cells to achieve a physiologically relevant effect, and they do not, therefore, suggest a usefulness of the adenovirus
10 system for use in connection with cancer therapy. Furthermore, prior to the present invention, it was thought that *p53* could not be incorporated into a packaging cell, such as those used to prepare adenovirus, as it would be toxic. As E1B of adenovirus binds to *p53*, this was thought to be a further reason why adenovirus and *p53* technology could not be combined.

15

Other Viral Vectors as Expression Constructs

Other viral vectors may be employed as expression constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988) adeno-associated virus (AAV)
20 (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska, 1984) and herpesviruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988; Horwich *et al.*, 1990).

25 With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. *in vitro* studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwich *et al.*, 1990). This suggested that large portions of the genome could be replaced with

-28-

foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang *et al.* recently introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang *et al.*, 1991).

10 C. Alternative Methods for Gene Delivery

In order to effect expression of *p53* constructs, the expression vector must be delivered into a cell. As described above, the preferred mechanism for delivery is via viral infection where the expression vector is encapsidated in an infectious adenovirus particle.

Several non-viral methods for the transfer of expression vectors into cultured mammalian cells also are contemplated by the present invention. These include calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa *et al.*, 1986; Potter *et al.*, 1984), direct microinjection (Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley *et al.*, 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer *et al.*, 1987), gene bombardment using high velocity microprojectiles (Yang *et al.*, 1990), polycations (Boussif *et al.*, 1995) and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use.

-29-

In one embodiment of the invention, the adenoviral expression vector may simply consist of naked recombinant vector. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. For example, Dubensky *et al.* (1984) successfully
5 injected polyomavirus DNA in the form of CaPO_4 precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of CaPO_4 precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding an *p53* construct may also be transferred in a similar
10 manner *in vivo*.

Another embodiment of the invention for transferring a naked DNA expression vector into cells may involve particle bombardment. This method depends on the ability to accelerate DNA coated microprojectiles to a high velocity allowing
15 them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang *et al.*, 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

20

Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded *in vivo* (Yang *et al.*, 1990; Zelenin *et al.*, 1991). This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ. DNA encoding a *p53* construct may be
25 delivered via this method.

In a further embodiment of the invention, the expression vector may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar

-30-

liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also contemplated are lipofectamine-DNA complexes.

Liposome-mediated polynucleotide delivery and expression of foreign DNA *in vitro* has been very successful. Wong *et al.* (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells. Nicolau *et al.* (1987) accomplished successful liposome-mediated gene transfer in rats after intravenous injection.

In certain embodiments of the invention, the liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda *et al.*, 1989). In other embodiments, the liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato *et al.*, 1991). In yet further embodiments, the liposome may be complexed or employed in conjunction with both HVJ and HMG-1. In that such expression vectors have been successfully employed in transfer and expression of a polynucleotide *in vitro* and *in vivo*, then they are applicable for the present invention. Where a bacteriophage promoter is employed in the DNA construct, it also will be desirable to include within the liposome an appropriate bacteriophage polymerase.

Another mechanism for transferring expression vectors into cells is receptor-mediated delivery. This approach takes advantage of the selective uptake of macromolecules by receptor-mediated endocytosis in almost all eukaryotic cells. Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993). Receptor-mediated gene targeting vehicles

-31-

generally consist of two components: a cell receptor-specific ligand and a DNA-binding agent. Several ligands have been used for receptor-mediated gene transfer. The most extensively characterized ligands are asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner *et al.*, 1993). Recently, a synthetic
5 neoglycoprotein, which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol *et al.*, 1993; Perales *et al.*, 1994) and epidermal growth factor (EGF) has also been used to deliver genes to squamous carcinoma cells (Myers, EPO 0273085).

10 In other embodiments, the delivery vehicle may comprise a ligand and a liposome. For example, Nicolau *et al.* (1987) employed lactosyl-ceramide, a galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes. Thus, it is feasible that an adenoviral expression vector also may be specifically delivered into a cell type such as
15 lung, epithelial or tumor cells, by any number of receptor-ligand systems, with or without liposomes. For example, epidermal growth factor (EGF) may be used as the receptor for mediated delivery of *p53* construct in many tumor cells that exhibit upregulation of EGF receptor. Mannose can be used to target the mannose receptor on liver cells. Also, antibodies to CD5 (CLL), CD22 (lymphoma), CD25 (T-cell
20 leukemia) and MAA (melanoma) can similarly be used as targeting moieties.

In certain embodiments, gene transfer may more easily be performed under *ex vivo* conditions. *Ex vivo* gene therapy refers to the isolation of cells from an animal, the delivery of a polynucleotide into the cells, *in vitro*, and then the return of the
25 modified cells back into an animal. This may involve the surgical removal of tissue/organs from an animal or the primary culture of cells and tissues. Anderson *et al.*, U.S. Patent 5,399,346, and incorporated herein in its entirety, disclose *ex vivo* therapeutic methods. During *ex vivo* culture, the expression vector can express the *p53* construct. Finally, the cells may be reintroduced into the original animal, or

administered into a distinct animal, in a pharmaceutically acceptable form by any of the means described below.

D. Pharmaceutical Compositions and Routes of Administration

5

Where clinical application of an adenoviral expression vector according to the present invention is contemplated, it will be necessary to prepare the complex as a pharmaceutical composition appropriate for the intended application. Generally this will entail preparing a pharmaceutical composition that is essentially free of pyrogens, as well as any other impurities that could be harmful to humans or animals. One also will generally desire to employ appropriate salts and buffers to render the complex stable and allow for complex uptake by target cells.

Aqueous compositions of the present invention comprise an effective amount of the expression vector, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Such compositions also are referred to as inocula. The phrases "pharmaceutically or pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.

Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as

hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

5

The expression vectors and delivery vehicles of the present invention may include classic pharmaceutical preparations. Administration of therapeutic compositions according to the present invention will be via any common route so long as the target tissue is available via that route. This includes oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration will be by orthotopic, intradermal, intraocular, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients.

15

The therapeutic compositions of the present invention are advantageously administered in the form of injectable compositions either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. These preparations also may be emulsified. A typical composition for such purpose comprises a pharmaceutically acceptable carrier. For instance, the composition may contain 10 mg, 25 mg, 50 mg or up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, *etc.* Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial agents, anti-oxidants, chelating agents and inert gases. The pH and

20

25

exact concentration of the various components the pharmaceutical composition are adjusted according to well known parameters.

Additional formulations are suitable for oral administration. Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. The compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders. When the route is topical, the form may be a cream, ointment, salve, liquid or spray.

10

An effective amount of the therapeutic agent is determined based on the intended goal, for example (i) inhibition of tumor cell proliferation or (ii) elimination of tumor cells. The term "unit dose" refers to physically discrete units suitable for use in a subject, each unit containing a predetermined-quantity of the therapeutic composition calculated to produce the desired responses, discussed above, in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the subject to be treated, the state of the subject and the protection desired. Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual.

15
20

In certain embodiments, it may be desirable to provide a continuous supply of therapeutic compositions to the patient. For intravenous or intraarterial routes, this is accomplished by drip system. For topical applications, repeated application would be employed. For various approaches, delayed release formulations could be used that provided limited but constant amounts of the therapeutic agent over an extended period of time. For internal application, continuous perfusion of the region of interest may be preferred. This could be accomplished by catheterization, post-operatively in some cases, followed by continuous administration of the therapeutic agent. The time

25

-35-

period for perfusion would be selected by the clinician for the particular patient and situation, but times could range from about 1-2 hours, to 2-6 hours, to about 6-10 hours, to about 10-24 hours, to about 1-2 days, to about 1-2 weeks or longer. Generally, the dose of the therapeutic composition via continuous perfusion will be
5 equivalent to that given by single or multiple injections, adjusted for the period of time over which the injections are administered. It is believed that higher doses may be achieved via perfusion, however.

Clinical Protocol for SCCHN

10 A clinical protocol has been developed to facilitate the treatment of SCCHN disease using the adenoviral constructs discussed below in the examples. In accordance with this protocol, patients having histologic proof of squamous cell carcinoma of the head and neck will be selected. Patients may, but need not have received previous chemo-, radio- or gene therapies. Optimally, patients will have
15 adequate bone marrow function (defined as peripheral absolute granulocyte count of $> 2,000/\text{mm}^3$ and platelet count of $100,000/\text{mm}^3$), adequate liver function (bilirubin $\leq 1.5 \text{ mg/dl}$) and adequate renal function (creatinine $< 1.5 \text{ mg/dl}$).

The protocol calls for single dose administration, via intratumoral injection, of
20 a pharmaceutical composition containing between 10^6 and 10^9 infectious particles of a *p53* adenovirus expression construct. For tumors of $\geq 4 \text{ cm}$, the volume administered will be 4-10 ml (preferably 10 ml), while for tumors $< 4 \text{ cm}$, a volume of 1-3 ml will be used (preferably 3 ml). Multiple injections will be delivered for a single dose, in 0.1-0.5 ml volumes, with spacing of approximately 1 cm or more.

25

The treatment course consists of about six doses, delivered over two weeks. Upon election by the clinician, the regimen may be continued, six doses each two weeks, or on a less frequent (monthly, bimonthly, quarterly, *etc.*) basis.

-36-

Where patients are eligible for surgical resection, the tumor will be treated as described above for at least two consecutive two-week treatment courses. Within one week of completion of the second (or more, *e.g.*, third, fourth, fifth, sixth, seventh, eighth, *etc.*) course, the patient will receive surgical resection. Prior to close of the incision, 10 ml of a pharmaceutical composition containing the *p53* adenovirus expression construct (10^6 - 10^9 infectious particles) will be delivered to the surgical site (operative bed) and allowed to remain in contact for at least 60 minutes. The wound is closed and a drain or catheter placed therein. On the third post-operative day, additional 10 ml of the pharmaceutical composition is administered via the drain and allowed to remain in contact with the operative bed for at least two hours. Removal by suction is then performed, and the drain removed at a clinically appropriate time.

Treatment of Artificial and Natural Body Cavities

One of the prime sources of recurrent SCCHN is the residual, microscopic disease that remains at the primary tumor site, as well as locally and regionally, following tumor excision. In addition, there are analogous situations where natural body cavities are seeded by microscopic tumor cells. The effective treatment of such microscopic disease would present a significant advance in therapeutic regimens.

Thus, in certain embodiments, a cancer may be removed by surgical excision, creating a "cavity." Both at the time of surgery, and thereafter (periodically or continuously), the therapeutic composition of the present invention is administered to the body cavity. This is, in essence, a "topical" treatment of the surface of the cavity. The volume of the composition should be sufficient to ensure that the entire surface of the cavity is contacted by the expression construct.

In one embodiment, administration simply will entail injection of the therapeutic composition into the cavity formed by the tumor excision. In another embodiment, mechanical application via a sponge, swab or other device may be

-37-

desired. Either of these approaches can be used subsequent to the tumor removal as well as during the initial surgery. In still another embodiment, a catheter is inserted into the cavity prior to closure of the surgical entry site. The cavity may then be continuously perfused for a desired period of time.

5

In another form of this treatment, the "topical" application of the therapeutic composition is targeted at a natural body cavity such as the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, or hollow organ cavities including the bladder, colon or other visceral organs. In this situation, there may or may not be a significant, primary tumor in the cavity. The treatment targets microscopic disease in the cavity, but incidentally may also affect a primary tumor mass if it has not been previously removed or a pre-neoplastic lesion which may be present within this cavity. Again, a variety of methods may be employed to affect the "topical" application into these visceral organs or cavity surfaces. For example, the oral cavity in the pharynx may be affected by simply oral swishing and gargling with solutions. However, topical treatment within the larynx and trachea may require endoscopic visualization and topical delivery of the therapeutic composition. Visceral organs such as the bladder or colonic mucosa may require indwelling catheters with infusion or again direct visualization with a cystoscope or other endoscopic instrument. Cavities such as the pleural and peritoneal cavities may be accessed by indwelling catheters or surgical approaches which provide access to those areas.

10

15

20

Monitoring *p53* Expression Following Administration

Another aspect of the present invention involves the monitoring of *p53* expression following administration of the therapeutic composition. Because destruction of microscopic tumor cells cannot be observed, it is important to determine whether the target site has been effectively contacted with the expression construct. This may be accomplished by identifying cells in which the expression construct is actively producing the *p53* product. It is important, however, to be able

25

-38-

to distinguish between the exogenous *p53* and that present in tumor and non-tumor cells in the treatment area. Tagging of the exogenous *p53* with a tracer element would provide definitive evidence for expression of that molecule and not an endogenous version thereof.

5

One such tracer is provided by the FLAG biosystem (Hopp *et al.*, 1988). The FLAG polypeptide is an octapeptide (AspTyrLysAspAspAspLys) and its small size does not disrupt the expression of the delivered gene therapy protein. The coexpression of FLAG and the protein of interest is traced through the use of antibodies raised against FLAG protein.

10

Other immunologic marker systems, such as the 6XHis system (Qiagen) also may be employed. For that matter, any linear epitope could be used to generate a fusion protein with *p53* so long as (i) the immunologic integrity of the epitope is not compromised by the fusion and (ii) the functional integrity of *p53* is not compromised by the fusion.

15

E. Combined Therapy Protocols

20

Tumor cell resistance to DNA damaging agents represents a major problem in clinical oncology. One goal of current cancer research is to find ways to improve the efficacy of chemo- and radiotherapy by combining it with gene therapy. For example, the herpes simplex-thymidine kinase (HS-tK) gene, when delivered to brain tumors by a retroviral vector system, successfully induced susceptibility to the antiviral agent ganciclovir (Culver, *et al.*, 1992). In the context of the present invention, it is contemplated that *p53* therapy could be used similarly in conjunction with chemo- or radiotherapeutic intervention.

25

-39-

To kill cells, such as malignant or metastatic cells, using the methods and compositions of the present invention, one would generally contact a "target" cell with an expression vector and at least one DNA damaging agent. These compositions would be provided in a combined amount effective to kill or inhibit proliferation of the cell. This process may involve contacting the cells with the expression vector and the DNA damaging agent(s) or factor(s) at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the *p53* expression vector and the other includes the DNA damaging agent.

Alternatively, the *p53* treatment may precede or follow the DNA damaging agent treatment by intervals ranging from minutes to weeks. In embodiments where the DNA damaging factor and *p53* expression vector are applied separately to the cell, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the DNA damaging agent and expression vector would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one would contact the cell with both agents within about 6 hours to one week of each other and, more preferably, within about 24-72 hours of each other, with a delay time of only about 48 hours being most preferred. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

It also is conceivable that more than one administration of either the *p53* construct or the DNA damaging agent will be desired. Various combinations may be employed, where *p53* is "A" and the DNA damaging agent is "B":

-40-

A/B/A	B/A/B	B/B/A	A/A/B	B/A/A	A/B/B	A/B/B/B
B/B/B/A	B/B/A/B	A/A/B/B	A/B/A/B	A/B/B/A	B/B/A/A	B/A/B/B
B/A/B/A	B/A/A/B	A/A/A/B	B/A/A/A	A/B/A/A	A/A/B/A	B/A/A/B

To achieve cell killing, both agents are delivered to a cell in a combined amount effective to kill the cell.

5 DNA damaging agents or factors are defined herein as any chemical compound or treatment method that induces DNA damage when applied to a cell. Such agents and factors include radiation and waves that induce DNA damage such as, γ -irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, and the like. A variety of chemical compounds, also described as "chemotherapeutic agents",

10 function to induce DNA damage, all of which are intended to be of use in the combined treatment methods disclosed herein. Chemotherapeutic agents contemplated to be of use, include, *e.g.*, adriamycin, 5-fluorouracil (5FU), etoposide (VP-16), camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP) and even hydrogen peroxide. The invention also encompasses the use of a combination of one or more

15 DNA damaging agents, whether radiation-based or actual compounds, such as the use of X-rays with cisplatin or the use of cisplatin with etoposide. In certain embodiments, the use of cisplatin in combination with a *p53* expression vector is particularly preferred.

20 In treating cancer according to the invention, one would contact the tumor cells with a DNA damaging agent in addition to the expression vector. This may be achieved by irradiating the localized tumor site with DNA damaging radiation such as X-rays, UV-light, g-rays or even microwaves. Alternatively, the tumor cells may be contacted with the DNA damaging agent by administering to the subject a

25 therapeutically effective amount of a pharmaceutical composition comprising a DNA damaging compound such as, adriamycin, 5-fluorouracil, etoposide, camptothecin,

-41-

actinomycin-D, mitomycin C, or more preferably, cisplatin. The DNA damaging agent may be prepared and used as a combined therapeutic composition, or kit, by combining it with a *p53* expression vector, as described above.

5 Agents that directly cross-link polynucleotides, specifically DNA, are envisaged and are shown herein, to eventuate DNA damage leading to a synergistic antineoplastic combination. Agents such as cisplatin, and other DNA alkylating may be used. Cisplatin has been widely used to treat cancer, with efficacious doses used in clinical applications of 20 mg/m² for 5 days every three weeks for a total of three
10 courses. Cisplatin is not absorbed orally and must therefore be delivered via injection intravenously, subcutaneously, intratumorally or intraperitoneally.

Agents that damage DNA also include compounds that interfere with DNA replication, mitosis and chromosomal segregation. Such chemotherapeutic
15 compounds include adriamycin, also known as doxorubicin, etoposide, verapamil, podophyllotoxin, and the like. Widely used in a clinical setting for the treatment of neoplasms, these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m² at 21 day intervals for adriamycin, to 35-50 mg/m² for etoposide intravenously or double the intravenous dose orally.

20

Agents that disrupt the synthesis and fidelity of polynucleotide precursors and subunits also lead to DNA damage. As such a number of polynucleotide precursors have been developed. Particularly useful are agents that have undergone extensive testing and are readily available. As such, agents such as 5-fluorouracil (5-FU), are
25 preferentially used by neoplastic tissue, making this agent particularly useful for targeting to neoplastic cells. Although quite toxic, 5-FU, is applicable in a wide range of carriers, including topical, however intravenous administration with doses ranging from 3 to 15 mg/kg/day being commonly used.

-42-

Other factors that cause DNA damage and have been used extensively include what are commonly known as γ -rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of DNA damage, or the precursors of DNA, the replication and repair of DNA, and the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

The skilled artisan is directed to "Remington's Pharmaceutical Sciences" 15th Edition, chapter 33, in particular pages 624-652. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

20

The inventor proposes that the regional delivery of *p53* expression vectors to patients with *p53*-linked cancers will be a very efficient method for delivering a therapeutically effective gene to counteract the clinical disease. Similarly, the chemo- or radiotherapy may be directed to a particular, affected region of the subject's body. Alternatively, systemic delivery of the expression vector or the DNA damaging agent may be appropriate in certain circumstances, for example, where extensive metastasis has occurred.

25

Cytokine therapy also has proven to be an effective partner for combined therapeutic regimens. Various cytokines may be employed in such combined approaches. Examples of cytokines include IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TGF- β , GM-CSF, M-CSF, 5 G-CSF, TNF α , TNF β , LAF, TCGF, BCGF, TRF, BAF, BDG, MP, LIF, OSM, TMF, PDGF, IFN- α , IFN- β , IFN- γ . Cytokines are administered according to standard regimens, as described below, consistent with clinical indications such as the condition of the patient and relative toxicity of the cytokine.

10 In addition to combining *p53*-targeted therapies with chemo-, radio and cytokine therapies, it also is contemplated that combination with other gene therapies will be advantageous. For example, targeting of *K-ras* and *p53* mutations at the same time may produce an improved anti-cancer treatment. Any other tumor-related gene conceivably can be targeted in this manner, for example, p21, p16, p27, E2F, Dp 15 family of genes, Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, FCC, MCC, other ras molecules, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, and *abl*. It also may be desirable to combine *p53* therapy with an antibody-based gene therapy treatment involving the use of a single-chain antibody construct in which the antibody binds to any of the foregoing molecules, or in 20 combination with genes encoding one or more of the cytokines listed above. It also may be advantageous to combine *p53* with other genes that have been implicated in apoptotic processes, *e.g.*, adenovirus E1A, Bax, Bcl-X_s, *etc.*

F. Kits

25

All the essential materials and reagents required for inhibiting tumor cell proliferation may be assembled together in a kit. This generally will comprise selected adenoviral expression vectors. Also included may be various media for

-44-

replication of the expression vectors and host cells for such replication. Such kits will comprise distinct containers for each individual reagent.

When the components of the kit are provided in one or more liquid solutions, the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being particularly preferred. For *in vivo* use, the expression vector may be formulated into a pharmaceutically acceptable syringeable composition. In this case, the container means may itself be an inhalent, syringe, pipette, eye dropper, or other such like apparatus, from which the formulation may be applied to an infected area of the body, such as the lungs, injected into an animal, or even applied to and mixed with the other components of the kit.

The components of the kit may also be provided in dried or lyophilized forms. When reagents or components are provided as a dried form, reconstitution generally is by the addition of a suitable solvent. It is envisioned that the solvent also may be provided in another container means.

The kits of the present invention also will typically include a means for containing the vials in close confinement for commercial sale such as, *e.g.*, injection or blow-molded plastic containers into which the desired vials are retained. Irrespective of the number or type of containers, the kits of the invention also may comprise, or be packaged with, an instrument for assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal. Such an instrument may be an inhalent, syringe, pipette, forceps, measured spoon, eye dropper or any such medically approved delivery vehicle.

G. Animal Model for Microscopic Tumor Seeding and Residual Disease

Another aspect of the present invention involves the development of an animal
5 model for the analysis of microscopic residual carcinomas and microscopic seeding of
body cavities. "Carcinoma," as used herein, may refer to a single cell or a
multicellular tumor mass. In microscopic disease, the "tumor" will consist of one or
a few carcinoma cells which cannot be observed with the naked eye.

10 The animal model described herein is particularly advantageous mimicking (i)
the post surgical environment of head and neck cancer patients, particularly in
advanced stages of disease and (ii) the body cavity of an affected subject wherein
microscopic carcinoma has been established. The model, similar to other animal
models for cancer, derives from inoculation of tumor cells into an animal. A
15 distinction, however, lies in the creation, subcutaneously, of a pouch that is a
physiologic equivalent of a natural body cavity or a post-surgical cavity created by the
excision of a tumor mass.

The instant inventions exemplifies nude mice as the model organism.
20 Virtually any animal may be employed, however, for use according to the present
invention. Particularly preferred animals will be small mammals that are routinely
used in laboratory protocols. Even more preferred animals will be those of the rodent
group, such as mice, rats, guinea pigs and hamsters. Rabbits also are a preferred
species. The criteria for choosing an animal will be largely dependent upon the
25 particular preference of an investigator.

The first step is to create a tissue flap in the experimental animal. The term
"tissue flap" means any incision in the flesh of the animal that exposes the target
tissue. It is generally preferred that an incision be made in the dorsal flank of an

-46-

animal, as this represents a readily accessible site. However, it will be understood that an incision could well be made at other points on the animal, and the choice of tissue sites may be dependent upon various factors such as the particular type of therapeutics that are being investigated.

5

Once a target tissue site is exposed, carcinoma cells, either individually or in microscopic tumors, are contacted with the tissue site. The most convenient manner for seeding the cancer cells into the tissue site is to apply a suspension of tissue culture media containing the cells to the exposed tissue. Cancer cell application may be achieved simply using a sterile pipette or any other convenient applicator. Naturally, this procedure will be conducted under sterile conditions.

In one embodiment, 2.5×10^6 SCCHN cells are inoculated into the exposed tissue flap of a nude mouse. Those of skill in the art will be able to readily determine, for a given purpose, what the appropriate number of cells will be. The number of cells will be dependent upon various factors, such as the size of the animal, the site of incision, the replicative capacity of the tumor cells themselves, the time intended for tumor growth, the potential anti-tumor therapeutic to be tested, and the like. Although establishing an optimal model system for any particular type of tumor may require a certain adjustment in the number of cells administered, this in no way represents an undue amount of experimentation. Those skilled in the area of animal testing will appreciate that such optimization is required.

This can be accomplished, for example, by conducting preliminary studies in which differing numbers of cells are delivered to the animal and the cell growth is monitored following resealing of the tissue flap. Naturally, administering larger numbers of cells will result in a larger population of microscopic residual tumor cells.

-47-

In the present study the flaps were effectively sealed using mattress sutures. However, it is envisioned that persons skilled in the art may use any of a variety of methods routinely used to seal the incision such as the use of adhesives, clamps, stitches, sutures, *etc.*, depending on the particular use contemplated.

5

H. Examples

The following examples are provided merely to illustrate certain specific embodiments and should not be considered as limiting the scope of the invention in any way.

10

EXAMPLE 1

Growth Suppression of Human Head and Neck Cancer Cells by the Introduction of a Wild-Type *p53* Gene via a Recombinant Adenovirus

15

Materials and Methods

Cell Lines and Culture Conditions. Human SCCHN cell lines Tu-138 and Tu-177 were both established at the Department of Head and Neck Surgery, M.D. Anderson Cancer Center. Tu-138 and Tu-177 were established from a gingivo-labial moderately differentiated squamous carcinoma and a poorly differentiated squamous carcinoma of the larynx, respectively. Both cell lines were developed via primary explant technique and are cytokeratin positive and tumorigenic in athymic nude and SCID mice. These cells were grown in DMEM/F12 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) with penicillin/streptomycin.

20

Recombinant Adenovirus Preparation and Infection. The recombinant *p53* adenovirus (Ad5CMV-*p53*) (Zhang *et al.*, 1994) contains the cytomegalovirus (CMV) promoter, wild-type *p53* cDNA, and SV40 polyadenylation signal in a mini-gene cassette inserted into the E1-deleted region of modified adenovirus type 5 (Ad5).

25

-48-

Viral stocks were propagated in 293 cells. Cells were harvested 36-40h after infection, pelleted, resuspended in phosphate-buffered saline, lysed, and cell debris was removed by subjecting to CsCl gradient purification. Concentrated virus was dialyzed, aliquoted and stored at -80°C. Infection was carried out by addition of the virus in DMEM/F12 medium and 2% FBS to cell monolayers, the cells were incubated at 37°C for 60 min with constant agitation, then complete medium (DMEM/F12/10% FBS) was added and the cells were incubated at 37°C for the desired length of time.

Northern Blot Analysis. Total RNA was isolated by the acid-guanidinium thiocyanate method of (Chomczynski and Sacchi, 1987). Northern analyses were performed on 20 µg of total RNA. The membrane was hybridized with a *p53* cDNA probe labeled by the random primer method in 5 x SSC/5X Denhardt's solution/0.5% SDS/denatured salmon sperm DNA (20 µg/ml). The membrane was also stripped and reprobed with GAPDH cDNA for RNA loading control. The relative quantities of *p53* expressed were determined by densitometer (Molecular Dynamics Inc., Sunnyvale, CA).

Western Blot Analysis. Total cell lysates were prepared by sonicating the cells 24-h post-infection in RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris, pH 8.0) for 5s. Fifty micrograms of protein from samples were subjected to 10% SDS-PAGE and transferred to Hybond-ECL membrane (Amersham). The membrane was blocked with Blotto/Tween (5% nonfat dry milk, 0.2% Tween 20, 0.02% sodium azide in phosphate-buffered saline) and probed with the primary antibodies, mouse anti-human *p53* monoclonal antibody PAb1801 and mouse anti-human β-actin monoclonal antibody (Amersham), and the secondary antibody, horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim, Indianapolis, IN). The membrane was processed and developed as the manufacturer suggested.

Immunohistochemical Analysis. The infected cell monolayers were fixed with 3.8% formalin and treated with 3% H₂O₂ in methanol for 5 min. Immunohistochemical staining was performed by using the Vectastain Elite kit (Vector, Burlingame, CA). The primary antibody used was the anti-*p53* antibody PAb1801, and the secondary antibody was an avidin-labeled anti-mouse IgG (Vector). The biotinylated horseradish peroxidase ABC complex reagent was used to detect the antigen-antibody complex. Preadsorption controls were used in each immunostaining experiment. The cells were then counterstained with Harris hematoxylin (Sigma Chemical Co., St. Louis, MO).

Cell Growth Assay. Cells were plated at a density of 2×10^4 cells/ml in 6-well plates in triplicate. Cells were infected with either wild-type (Ad5CMV-*p53*) or replication-deficient adenovirus as a control. Cells were harvested every 2 days, counted and their viability was determined by trypan blue exclusion.

Inhibition of Tumor Growth *In Vivo*. The effect of Ad5CMV-*p53* on established subcutaneous tumor nodules was determined in nude mice in a defined pathogen free environment. Experiments were reviewed and approved by institutional committees for both animal care and utilization and for recombinant DNA research. Briefly, following induction of acepromazine/ketamine anesthesia, three separate subcutaneous flaps were elevated on each animal and 5×10^6 cells in 150 ml of complete media were injected subcutaneously into each flap using a blunt needle; the cells were kept in the pocket with a horizontal mattress suture. Four animals were used for each cell line. After 4 days, the animals were re-anesthetized and the flaps were re-elevated for the delivery of 100 ml of 1) Ad5CMV-*p53* (50 MOI) in the right anterior flap; 2) replication-defective virus (50 MOI) in the right posterior flap; and 3) transport medium alone, in the left posterior flank. All injection sites had developed subcutaneous visual and palpable nodules before treatment was

-50-

administered. Animals were observed daily and sacrificed on day 20. *in vivo* tumor volume was calculated by assuming a spherical shape with the average tumor diameter calculated as the square root of the product of cross-sectional diameters. Following sacrifice, excised tumors were measured 3-dimensionally by microcalipers to
5 determine tumor volume. A non-parametric Friedman's 2-way ANOVA test was used to test the significance of the difference between means of samples; the SPSS/PC+ software package (SPSS Inc., Chicago, Il) was used.

Results

10 **Adenoviral Infection of SCCHN Cells.** The conditions for optimal adenoviral transduction of Tu-138 and Tu-177 cells were determined by infecting these cells with adenovirus expressing the E. coli β -gal gene. The transduction efficiency was assessed by counting the number of blue cells after X-gal staining. There appeared to be a linear relationship between the number of infected cells and
15 the number of adenovirus particles used. Cells inoculated with a single dose of 100 MOI β -gal adenovirus exhibited 60% blue cells (FIG. 1), and this was improved to 100% by multiple infections. The transduction efficiency of this vector in SCCHN cells is quite different from that of other cell lines previously examined: HeLa, HepG2, LM2 and human non-small cell lung cancer cell lines showed 97% to 100%
20 infection efficiencies after incubation with 30 to 50 MOI β -gal adenovirus (Zhang *et al.*, 1994).

Expression of Exogenous *p53* mRNA in Adenovirus Infected SCCHN Cells. Two human SCCHN cell lines were chosen for this study: both cell lines
25 Tu-138 and Tu-177 possess a mutated *p53* gene. The recently created recombinant wild-type *p53* adenovirus, Ad5CMV-*p53*, was used to infect Tu-138 and Tu-177 cells. Twenty-four hours after infection, total RNA was isolated and northern blot analysis was performed. The transformed primary human embryonal kidney cell line 293 was used as a positive control because of its high level of expression of the *p53*

-51-

gene product, whereas K562, a lymphoblastoma cell line with a homozygous deletion of the *p53* gene, was the negative control. The levels of the 2.8-kb endogenous *p53* mRNA detected in the samples isolated from mock-infected cells and from the cells infected with a replication-defective adenovirus, dl312 were similar. Up to 10-fold higher levels of exogenous 1.9-Kb *p53* mRNA were present in the cells infected with Ad5CMV-*p53*, indicating that the exogenous *p53* cDNA was successfully transduced into these cells and efficiently transcribed. Interestingly, the level of endogenous *p53* mRNA in these cells was 5-fold higher than in the experimental controls. Northern blots exhibited no evidence of Ad5CMV-*p53* (DNA) contamination of RNA.

10

Expression of *p53* Protein in Adenovirus-Infected SCCHN Cells. Western blot analysis was performed to compare the levels of *p53* mRNA to the amount of *p53* protein produced. A *p53* band, recognized by monospecific anti-*p53* antibody, PAb1801, was observed in cellular extracts isolated from all samples except K562 cells. Cell line 293 showed high levels of *p53* protein. Samples isolated from mock-infected Tu-138 and Tu-177 cells exhibited low levels of *p53* protein. The level of *p53* expression remained similar in those cells infected with the dl312 adenovirus. The levels of *p53* antigen detected in Ad5CMV-*p53*-infected cells were significantly higher than the levels of the endogenous mutated proteins in both cell lines. This result demonstrates that the exogenous *p53* mRNA produced from cells infected with Ad5CMV-*p53* is efficiently translated into immunoreactive *p53* protein. Furthermore, immunohistochemical analysis of cells infected with Ad5CMV-*p53* revealed the characteristic nuclear staining of *p53* protein, while mock-infected cells failed to show similar staining despite the presence of the *p53* protein in these cells. This inability to detect the protein may be attributable to the insensitivity of the assay.

25

Effect of Exogenous *p53* on SCCHN Cell Growth *In Vitro*. Cells infected with control virus dl312 had growth rates similar to those of the mock-infected cells (FIG. 2A and 2B), whereas, growth of the Ad5CMV-*p53*-infected Tu-138 (FIG. 2A)

-52-

and Tu-177 (FIG. 2B) cells was greatly suppressed. Twenty-four hours after infection, an apparent morphologic change occurred, with portions of the cell population rounding up and their outer membranes forming blebs. These are part of a series of histologically predictable events that constitute programmed cell death. The effect was more prominent for Tu-138 than for Tu-177 cells. Cells infected with the replication-defective adenovirus, dl312, demonstrated normal growth characteristics with no histomorphologic abnormalities. Growth assays were reproducible in four repeated experiments.

Inhibition of Tumor Growth *In Vivo*. Four animals were tested for each cell lines. One animal in the Tu-177 group died following the second flap surgery and delivery of the therapeutic interventions, presumably due to profound anesthesia and subsequent mutilation by cage mates. Necropsy revealed no evidence of metastasis or systemic effects. Sizable tumors are apparent on both posterior flaps of the animals (i.e., the sites that did not receive Ad5CMV-*p53*). The lack of tumor progression is significant in the right anterior flaps of the animals, which received Ad5CMV-*p53* ($p < .04$). That Tu-177 cells have a slower growth rate has previously been established in these animals. Two animals in the Tu-138 group were killed early because they were experiencing rapid growth and ulceration of the control tumor sites. All surgical sites had developed lesions of at least 9 mm³ before intervention. The tumor volumes on necropsy are shown in Table 4. Differences in volume were not statistically significant in the Tu-177 group which may be a reflection of the limited sample size.

-53-

TABLE 4

Effect of Ad5CMV-*p53* on Tumor Growth in Nude Mice^a

Treatment	Mean volume [mm ³ ± SEM]	
	TU-138(4)	Tu-177(3)
Ad5CMV- <i>p53</i>	36.0 ± 23.5	19 ± 14.9
Ad5(dl312)	1187.5 ± 419.0	226 ± 84.0
Medium	1909.3 ± 776.8	454 ± 276.8
Significance	<i>p</i> value	<i>p</i> value
<i>p53</i> ^b : dl312	0.04	0.09
<i>p53</i> : Medium	0.05	0.09

5 ^aThe cells were injected subcutaneously at 5×10^6 cells/flap. Tumor sizes were determined at day 20 after treatment. Numbers in parentheses represent the number of animals evaluated. ^bAd5CMV-*p53* is abbreviated as *p53*; dl312 as an abbreviation for Ad5(dl312).

EXAMPLE 2

10 *in vivo* Molecular Therapy with *p53* Adenovirus for
Microscopic Residual Head and Neck Squamous Carcinoma

Materials and Methods

15 **Cell Lines and Culture Conditions.** Human SCCHN cell lines Tu-138, Tu-177, MDA 686-LN, and MDA 886 were all established have been previously characterized (Clayman *et al.*, 1993; Sacks *et al.*, 1988). These cells were grown in Dulbecco's modified Eagle's medium (DMEM/F12) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and penicillin/streptomycin.

Recombinant Adenovirus Preparation and Infection; Cell Growth Assay; Western Blot Analysis. All the procedures have been previously described in Example 1. Cell growth assays were all performed in triplicate.

- 5 ***In Vivo* Transduction with β -Galactosidase Adenovirus.** X-gal staining of tissue specimens were performed on O.C.T. frozen tissue sections to determine transduction efficiency. Eight-micrometer thick specimens were washed in cold PBS and fixed in 0.5% glutaraldehyde at room temperature for 5 minutes. Slides were then washed twice with 4°C PBS and incubated 4 h in X-gal solution (1.3 mM
- 10 MgCl₂; 15 mM, NaCl; 44 mM Hepes Buffer pH7.4; 3 mM Potassium ferricyanide; 3 mM Potassium ferrocyanide; 2% X-gal in DMF). Slides were counterstained with hematoxylin and eosin.

- Immunohistochemical Analysis.** Formalin-fixed paraffin-embedded *in vivo*
- 15 animal experimental tissues were cut at 4-5 μ m, dried at 60°C, deparaffinized, and hydrated with distilled water. Sections were then treated with 0.5% saponin in distilled water and rinsed in several changes of distilled water; endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol, followed by rinsing in several changes of distilled water. Sections were microwave-irradiated in distilled
- 20 water for 3 min using a Sharp Model R9H81 microwave oven operating at a frequency of 2450 MHz at 700 watts. After cooling, sections were washed in several changes of distilled water and placed in PBS; immunochemical studies were performed by using the avidin-biotin-peroxidase complex (ABC) method of Hsu *et al.*, (1981) in the following manner: sections were blocked with normal horse serum
- 25 and incubated overnight at 4°C with rabbit anti-human p53 polyclonal antibody, clone OM-1, 1:80 (Signet Laboratories, Denham, MA). An anti-rabbit IgG Elite kit (Vector Laboratories, Burlingame, CA) was then used to apply biotinylated anti-rabbit IgG and ABC complexes, which were incubated for 45 min each. The immunostaining reaction was visualized by using 0.5% DAB in PBS containing

-55-

0.01% hydrogen peroxide (pH 7.6), counterstained with 0.01% toluidine blue, dehydrated, cleared, and mounted in Permount. To verify the specificity of the immunostaining reaction, immunoperoxidase staining was performed, using the same method as on test samples, on a known positive cytospin of a tissue culture of a squamous carcinoma cell line as well as on a negative rabbit monoclonal antibody control.

Inhibition of Tumor Growth *In Vivo*. This procedure was performed as described in Example 1. All surgical sites were evaluated pathologically as well as by necropsy analysis for systemic toxicity.

Results

Effect of Exogenous *p53* on SCCHN Cell Growth *In Vitro*. Example 1 described the *in vitro* inhibition of cell growth by Ad5CMV-*p53* in SCCHN cell lines with endogenously mutated *p53*. This present example is to determine whether SCCHN cell lines with endogenous wild-type *p53* would be similarly affected. The effect of Ad5CMV-*p53* on nonmalignant fibroblasts is also investigated.

Four human SCCHN cell lines were chosen for this study: Tu-138 and Tu-177 possess a mutated *p53* gene, whereas MDA 686-LN and 886 both are homozygous for the wild-type *p53* gene. A fibroblast cell line derived from normal fibroblast outgrowth, which is karyotypically normal and nontumorigenic, was used as a nonmalignant control cell line. Cells infected with the control virus, dl312, had growth rates similar to those of the mock-infected cells, whereas the growth of tumor cells infected with Ad5CMV-*p53* was significantly suppressed (FIG. 3A, FIG. 3B, FIG. 3C AND FIG. 3D). Twenty-four hours to forty-eight hours after infection, an apparent morphologic change occurred in all tumor cells, with portions of the cell population rounding up and their outer membranes forming blebs. These are part of a series of histologically predictable events that constitute programmed cell death. The

-56-

effect occurred earlier in cells with endogenous mutated *p53* than in those with wild-type *p53*. Cells infected with replication-defective adenovirus dl312 demonstrated normal growth characteristics with no histomorphologic abnormalities. Growth assays were reproducible in four repeated experiments.

5

Expression of Exogenous *p53* Protein in Adenovirus Infected Normal Fibroblasts and its Effect on Growth Rate. Additionally, the effect of the Ad5CMV-*p53* on karyotypically normal and non-tumorigenic fibroblast cell lines was also investigated. These cells were isolated during the establishment of primary tumor cell lines. Twenty-four hours after infection, Western blot analysis was performed to compare the levels of protein produced by the different infected cell types. A *p53* band, recognized by the monospecific anti-*p53* antibody, PAb1801, was observed in cellular extracts isolated from all samples infected with the Ad5CMV-*p53*. As has been in Example 1, cell line Tu-138 infected with the *p53* adenovirus showed high levels of *p53* protein following transduction and served as a control. The level of *p53* expression remained similar in both mock-infected and dl312 infected cells. The Ad5CMV-*p53* infected fibroblasts showed higher levels of *p53* protein than that of the control cells. This result indicates that the *p53* gene is efficiently translated into normal fibroblasts infected with Ad5CMV-*p53* as evidenced by production of immunoreactive *p53* protein. The protein expression and transduction efficiency of cytopins of Ad5CMV-*p53* infected fibroblasts were verified by immunohistochemical analysis. This fibroblast cell line exhibited normal growth rate and morphology, independent of the intervention (mock, replication-defective virus, or Ad5CMV-*p53*) (FIG. 4). These experiments were repeated twice and also verified in other normal human fibroblast cell lines.

25

***In Vivo* Transduction Efficiency.** To measure the efficiency of gene transfer *in vivo*, the subcutaneous flap site was resected 72 hours following the molecular or control intervention. Dose-response experiments with the adenovirus β -galactosidase

-57-

marker vector demonstrate dose-response transduction efficiency in this model. This was confirmed with immunohistochemical analysis 4 days following infection with Ad5CMV-*p53*. Both groups of experiments exhibited an *in vivo* dose response which had been previously described *in vitro* (Example 1). In no instances did doses of virus exceeding 10^{10} PFU effect expression of *p53* in other organ systems, including brain, liver, lung, heart, abdominal visceral organs, and skin. These experiments illustrated a dose-response relationship between viral titer and transduction efficiency as well as the possibility of achieving extensive transient expression of the transduced gene within the desired surgical model field.

10

Suppression of Tumor Growth *In Vivo*. Studies were designed to determine whether *in vivo* Ad5CMV-*p53* mediated gene transfer would affect the establishment or growth of SCCHN cells implanted into a subcutaneous flap. To achieve this aim a microscopic residual disease model was created. In this model, three subcutaneous flaps were elevated on athymic nude female mice and 2.5×10^6 of tumor cells were seeded by pipetting. Instead of allowing the tumor cells to form nodules (generally occurring in 4 days), a single dose of molecular intervention at 48 hours following tumor cells seeding. In this manner, although no gross tumors were present, microscopic tumor cells were within the surgical site mimicking the clinical dilemma of surgical excision of all gross tumor. The development of tumors was directly related to the number of tumor cells, the time allotted for implantation, and the dose of Ad5CMV-*p53*. Of the mice which received microscopically implanted tumor cells (2.5×10^6) and were treated with Ad5CMV-*p53* at 10^8 plaque forming units (PFU) or greater, only two developed tumors, both implanted with the wild-type *p53* cell line (MDA 886-LN). All other cell lines exhibited absence of tumor development (Table 5). These experiments clearly demonstrate that the growth of microscopic tumor cells can be effectively suppressed *in vivo* if exposed to the Ad5CMV-*p53*. Tumor formation was evaluated at the end of a 12 week period (earlier animal sacrifice in

15

20

25

circumstances of excessive tumor burden) by gross and histologic analysis of the surgical sites. The data of tumor establishment is summarized in Table 5.

TABLE 5

5

**Effect of Ad5CMV-*p53* on Tumorigenicity in a
Microscopic Residual Disease Model of SCCHN**

Cell Line	Treatment		
	No. Mice Developing Tumors/Total Mice		
	Vehicle		
	PBS	dl312	Ad5CMV- <i>p53</i>
Tu-138 (homozygous mutation <i>p53</i>)	8/8	8/8	0/8
Tu-177 (homozygous mutation <i>p53</i>)	8/8	8/8	0/8
686-LN (homozygous wild-type <i>p53</i>)	5/8	5/8	0/8
886 (homozygous wild-type <i>p53</i>)	6/6	6/6	2/6

Immunohistochemical analysis was performed on the tumor sections of experimental animals. This cell line possesses the wild-type endogenous *p53* gene.

10 There was a lack of significant basal immunostaining with viable tumor of MDA 686-LN (mock-infection). 10^7 PFU Ad5CMV-*p53* exhibits peripheral tumor necrosis with immunostaining in the more central portion of the tumor. 10^8 PFU Ad5CMV-*p53* reveals total necrosis of the tumor with immunostaining found in the entire surgical pocket with multiple layers expressing protein including stroma and

15 superficial muscular layers. 10^9 PFU Ad5CMV-*p53* shows similar results to that of 10^8 PFU Ad5CMV-*p53*, however increased exogenous *p53* expression throughout the surgical site and edema are prominent.

Using animals, which served as their own internal controls, implants of 4.0×10^6 or more cells significantly increased the establishment of subcutaneous implants as

20 compared to the tumor implantation of 2.5×10^6 cells ($P < 0.01$), even when treated

-59-

at the surgical site with Ad5CMV-*p53* 48 h after inoculation. Allowing implanted cells to establish for 72 or 96 h prior to the Ad5CMV-*p53* intervention similarly increased tumor take. Dose-response experiments established that 10^8 and 10^9 PFU of the Ad5CMV-*p53* were equally effective in inhibiting tumor burdens of 2.5×10^6 cells implanted for 48 h (FIG. 6). Endogenous *p53* status of implanted tumor cell lines (whether homozygous mutated or wild-type *p53*) had little impact on the effectiveness of the Ad5CMV-*p53* in the cessation of tumor development.

EXAMPLE 3

Apoptosis Induction Mediated by Wild-Type *p53* Adenovirus Gene Transfer in Squamous Cell Carcinoma of Head and Neck

Materials and Methods

Cell Lines and Culture Conditions; Recombinant Adenovirus Preparation and Infection. All procedures were performed and cell lines maintained as previously described in Examples 1 and 2.

DNA Fragmentation Analysis. Following incubation with wild-type *p53* adenovirus as well as replication defective adenovirus controls at various time intervals, cells were harvested, resuspended in 300 μ l of PBS with the addition of 3 ml of extraction buffer (10 mM Tris, pH 8.0, 0.1M EDTA, 20 μ g/ml RNase, 0.5% SDS) and incubated at 37°C for 1-2 h. At the end of incubation, proteinase K was added to a final concentration of 100 μ g/ml and the solution placed in a 50°C water bath for at least 3 h. DNA was extracted once with equal volume of 0.5 M Tris (pH 8.0) saturated phenol then the extraction repeated with phenol/chloroform. Precipitated DNA was analyzed in a 1% agarose gel.

Cell Fixation. For TUNEL method, the cells were fixed in 1% formaldehyde in PBS (pH 7.4) for 30 min on ice. Cells were then washed with 3 ml of PBS, resuspended in 70% ice-cold ethanol and stored at -20°C until used. For cell-cycle analysis, cells were fixed in 70% ice-cold ethanol only.

5

Terminal Deoxynucleotidyl Transferase Assay. The assay was performed according to Gorczyca *et al.*, procedure (Gorczyca *et al.*, 1993). Briefly, after fixation and washing, cells were resuspended in 50 µl of TdT buffer containing 0.2 M sodium cacodylate (pH 7.0), 2.5 mM Tris-HCl, 2.5 mM C_6Cl_2 (Sigma Chemical Company, St. Louis, MO), 0.1 mM DTT (Sigma Chemical Company), 0.25 mg/ml BSA (Sigma Chemical Company), 5 units of terminal transferase (Boehringer Mannheim Biochemicals, Indianapolis, IN), and 0.5 nmoles biotin-16-dUTP along with dATP, dGTP and dCTP at a concentration of 20 µM. Controls were prepared by incubating a separate aliquot of each test sample without d-UTP. The cells were incubated in the solution at 37°C for 30 min, rinsed in PBS, and resuspended in 100 µl of, FITC, the staining solution containing 4X SSC, 0.1% Triton X-100 and 2.5 µg/ml fluoresceinated avidin (Vector Labs. Inc., Burlingame, CA). Tubes were incubated for 30 min in the dark at room temperature. Cells were rinsed in PBS with 0.1% Triton X-100 and resuspended in 0.5 ml PBS containing propidium iodide (5 µg/ml) and 70 µl (1 mg/ml) RNase. Tubes were incubated in the dark on ice for 30 min prior to flow cytometric analysis.

Flow Cytometry Analysis. All samples were analyzed using an EPICS Profile II flow cytometer (Coulter Corp., Hialeah, FL) with the standard optical configuration. At least 5,000 events were collected for each sample. Positivity for TdT end-labeling was determined by subtracting the control histogram from the test histogram using the immuno-4 program of the Elite workstation software (Coulter Corp., Hialeah, FL).

-61-

Cell Growth Assay. Cells were plated and growth was monitored as described in Example 1.

***In Vivo* Analysis for Apoptosis.** Gene therapy in a microscopic residual
5 disease model of SCCHN has been described above in Example 2.

***In Situ* End-labeling.** The procedure was performed as previously described (Wijsman *et al.*, 1993). Briefly, paraffin sections were dewaxed in xylene for 5 min three times each, and progressively hydrated by immersing the slides for 3 min each
10 in 100%, 90%, 70% and 30% ethanol solutions. Endogenous peroxidase was inactivated by immersing the slides for 20 min in 0.75% H₂O₂ v/v in 100% methanol. After the slides were washed in PBS, sections were digested with 0.1% pepsin (Fisher Scientific, Houston, TX) w/v in 0.1 N HCl for 5 min at 37°C and extensively washed in PBS. Sections were then incubated in a moist chamber at 37°C for 1 h with an
15 end-labeling cocktail including the following: terminal deoxynucleotidyl transferase 0.5 unit/μl; biotinylated dUTP, 0.06 mM; 5X tdt buffer, 10 μl; double-distilled water up to 50 μl. The reaction was terminated by immersing the slides in a buffer containing 300 mM NaCl and 30 mM NaCitrate in double-distilled water. After the
20 slides were washed in PBS, sections were incubated with horseradish peroxidase-conjugated avidin for 1 h at 37°C in a moist chamber. Staining was developed using 3,3'-diaminobenzidine and sections were counterstained with methyl green.

Results

25 **Growth suppression of SCCHN cell lines by *p53* adenovirus.** The Examples above demonstrate that the wild-type *p53* gene can be efficiently transduced into SCCHN cell lines by a recombinant adenoviral vector. Consequently, the insulted tumor cells lose their ability to proliferate *in vitro* as well as *in vivo*. The suppression effect is independent of the endogenous *p53* status of the cell lines. Previous growth

rate analyses were carried out through a week period. The present example investigates the early effects of the wild-type *p53* on SCCHN cells growth (i.e. earlier time intervals, hours).

5 Two representative cell lines were used in this study. Cell line, Tu-138, harbors a mutated *p53* gene whereas cell line, MDA 686LN, possesses a wild-type *p53* gene. Cells infected with replication-defective virus, dl312, had growth rates similar to those of the mock-infected cells (FIG. 5A and FIG. 5B). On the other hand, growth of the Ad5CMV-*p53* infected Tu138 (FIG. 5A) and MDA 686LN (FIG. 10 5B) cells were significantly suppressed. It appeared that the exogenous *p53* protein had an earlier and more profound growth suppression of the Tu138 as compared to the MDA 686LN. An apparent morphologic change was observed, with portions of the cell populations rounding up and their outer membranes forming blebs, resembling apoptosis, which occurred concomitantly with the initiation of the growth suppression.

15 Cells infected with the replication-defective adenovirus, dl312, demonstrated normal growth characteristics with no histomorphologic abnormalities. Importantly, these effects were not observed following the *p53* adenovirus infection of karyotypically normal fibroblasts, as detailed in Example 2 above, as well as human oral keratinocytes (immortalized but nontumorigenic).

20

DNA fragmentation analysis. One of the characteristic markers in apoptosis that distinguishes it from necrosis is the biochemically observable appearance of the ladder of DNA fragments. To confirm the notion that the cells had undergone apoptosis following the *p53* adenovirus infection, performed DNA fragmentation analysis was performed. Chromosomal DNA extracted from the viable cells 25 following the replication-defective or the wild-type *p53* adenovirus infection were subjected to agarose gel electrophoresis. The appearance of DNA fragments equivalent to approximately 200 bp and their multiples was noticed in both cell lines.

The fragmented DNA appeared at 22 h following the *p53* adenovirus infection in

-63-

Tu-138 cell line whereas in the MDA 686LN cell line, fragmented DNA were visible at 30 h and more evident at 48 h following the wild-type *p53* adenovirus infection. No detectable fragmented DNA emerged from the mock-infected and dl312-infected cells.

5

In Vitro Terminal Deoxynucleotidyl Transferase Assay. Another characteristic marker of apoptosis is the morphological change and destruction of the structural organization of the nucleus which results in chromatin condensation. Electron microscopy has been used extensively to detect such ultra-structural alteration. However, recently flow cytometry methods for identifying apoptotic cells have gained favor due to the ability to scan and analyze cellular populations as compared to electron microscopy (Gorczyca *et al.*, 1993). The inventor employed here the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling) method (Gorczyca *et al.*, 1993) which is based upon detection of the extensive DNA breakage to identify the apoptotic cells. Fifteen h following the *p53* adenovirus infection, 4.4% of the viable Tu-138 cell population were in apoptotic stages as compared to none of the MDA 686LN (FIG. 6A and FIG. 6B). The number of apoptotic cells increased proportionally as the duration of observation was also increased following *p53* adenovirus incubation. Nearly 31% of the Tu-138 cells had undergone apoptosis at 22 h. Although delayed in initial induction of apoptosis, approximately 60% of the MDA 686LN cells were in apoptotic stages 48 h following the *p53* adenovirus infection. Noteworthy, the percentage of apoptotic cells as determined by Tunel method may be significantly underestimated since only viable cells were subjected to the analysis. These data correlated well with the growth rate and DNA fragmentation analyses. There were no detectable cell populations undergoing apoptosis in control experiments using mock infection as well as replication defective virus controls (100 M.O.I.). Therefore, the apoptosis was not the function of transduced adenoviral gene products themselves.

25

-64-

***In Vivo* Analysis for Apoptosis.** The examples above show that the *p53* adenovirus suppresses tumor formation *in vivo*. This example was designed to show whether the suppression of tumor growth *in vivo* was the consequence of apoptosis. *In situ* end-labeling analysis was performed to detect apoptotic cells in paraffin embedded sections obtained from example 2. Clearly, no staining was observed in the tissue sections isolated from MDA 686LN bearing animals which had received PBS treatment as a control. On the other hand, tissue sections isolated from MDA 686LN bearing mice treated with the wild-type *p53* adenovirus showed highly positive staining, demonstrating that apoptosis indeed was the event involved in suppression of tumor growth *in vivo*.

Further to these studies the inventor sought to determine whether the growth suppression is, in part, due to the cell cycle arrest by the induced p21 protein or primarily a result of apoptosis. Western blotting showed that the p21 protein was induced in the wild-type *p53* adenovirus infected SCCHN cells. However, cell cycle analyses indicated that despite the elevated level of p21 protein in the *p53* adenovirus infected cells, there was no significant accumulation of cells at the G₁ stage when compared to S phase.

20

EXAMPLE 4

Growth Suppression of Head and Neck Squamous Cells by *p53*-FLAG: an Effective Marker for Gene Therapy Trails

25

Materials and Methods.

Cell Lines and Culture Conditions. Recombinant Adenovirus Preparation and Infection; Northern Blot Analysis; Western Blot Analysis; Cell Growth Assay; Immunohistochemical Staining *in vitro* Cell Layers. All procedures were performed and cell lines maintained as described in Example 1.

Generation of the *p53*-FLAG Adenovirus. The *p53* cDNA sequence was excised from the *pC53-SN* by digestion with *Bam*HI and cloned into the *Bam*HI site of *pGEM7Z*. A recombinant plasmid with the proper insert orientation was then digested with *Acc*I and *Kpn*I to remove 22 amino acids from the 3' end of *p53* cDNA. A linker with *Acc*I-*Kpn*I compatible ends containing the sequence of the FLAG peptide including a stop codon was then ligated into the digested plasmid to create the *p53*-FLAG fusion gene. The resulting *p53*-FLAG fusion gene was then cloned into an expression vector with the human CMV promoter and SV polyadenylation signal. The final construct was subsequently inserted into a shuttle vector *pXCJL.1* ((Zhang *et al.*, 1994) to generate a recombinant *p53*-FLAG adenovirus.

***In Vivo* Microscopic Residual Disease Experiments.** The studies were carried out in a defined pathogen free environment using the athymic nude model system described in Example 1. Two different sets of repeated experiments were performed. The first was a dose-response experiment using the AdCMV-*p53*-FLAG virus in three of the flaps at descending concentrations (10^{10} pfu, 10^9 pfu, 10^8 pfu). The fourth flap served as a control and was randomized to either PBS or the replication defective adenovirus (DL312). The second study was performed using 10^{10} pfu of AdCMV-*p53*-FLAG, AdCMV-*p53*, and replication defective adenovirus in three separate flaps. The fourth flap was inoculated with the same volume (100 μ l) of sterile PBS. Forty eight hours after treatment, two of these animals were sacrificed and the flaps harvested for immunohistochemical analysis. The remaining animals were observed for 21 days and then sacrificed. Tumor volumes were measured for comparison using calipers.

Results

Expression of mRNA after Infection with AdCMV-*p53* and AdCMV-*p53*-FLAG Virus. Both Tu-138 and MDA 686-LN were examined for expression of *p53* mRNA. Total RNA was isolated after adenovirus infection. Northern blot analysis was performed. Similar levels of exogenous AdCMV-*p53* mRNA were detected between AdCMV-*p53* and AdCMV-*p53*-FLAG infected cells. The level of *p53* mRNA expression following infection with AdCMV-*p53* and AdCMV-*p53*-FLAG were comparable for Tu-138 and for MDA 686-LN. Variation of intensity is felt to be related to loading dose. Endogenous expression of *p53* mRNA is seen in lanes 2 and 3 in the mutated *p53* cell line, Tu-138. There was no significant endogenous *p53* mRNA expression in the MDA 686-LN cell line, which is wild-type for the *p53* gene. These data suggest that the AdCMV-*p53*-FLAG virus, like the AdCMV-*p53* virus, is successfully transduced and efficiently transcribed. Northern analysis did not reveal evidence of AdCMV-*p53* DNA contamination.

15

Expression of Exogenous *p53* Protein in AdCMV-*p53* and AdCMV-*p53*-FLAG Infected SCCHN Cell Lines. Western blot analysis was performed to compare the amount of protein expressed by the AdCMV-*p53* infected and AdCMV-*p53*-FLAG infected cells. Protein bands were identified using the monospecific *p53* antibody (PAb1801) and the anti-FLAG M2 antibody (IB13025) on two simultaneously run gels. Using the *p53* antibody (pAB1801), a similar high level of *p53* protein expression in both cell lines that were infected with the AdCMV-*p53* and AdCMV-*p53*-FLAG. The Tu-138 and MDA 686-LN cells infected with the AdCMV-*p53*, were also tested. No change in *p53* protein expression was noted in either the replication defective adenovirus infected cells or in the mock infection group. When a similarly executed gel that was probed with the mouse anti-FLAG M2 antibody. The level of *p53*-FLAG protein expression appeared to be similar to that expressed following *p53* antibody probing, but no detectable band was noted in those

25

-67-

cells infected with the AdCMV-*p53* virus. The mock and DL312 infected cells exhibited no detectable level of the immunoreactive *p53* or FLAG protein in either cell line.

- 5 **Effect of AdCMV-*p53* and AdCMV-*p53*-FLAG on SCCHN Cell Growth**
***In Vitro*.** The cytotoxic effect of wild-type *p53* therapy in Tu-138 and MDA 686-LN cell lines has been detailed above. The Tu-138 cell line has an endogenously mutated *p53* gene and the MDA 686-LN cell line possesses the wild-type *p53* gene. This study sought to determine if any difference in efficacy would be seen following
10 recombination of the AdCMV-*p53* virus by inserting the FLAG sequence.

- Cells infected with the replication defective adenovirus had a similar growth rate to the mock infection cells. A mild cytotoxic effect may be seen with the replication defective adenovirus (FIG. 7A). In contrast, those cells infected with
15 either the AdCMV-*p53* or AdCMV-*p53*-FLAG experienced virtual total tumor cell death by day three. Histologic examination revealed bleb formation by the plasma membrane which is the characteristic feature of apoptosis and has been characterized as the mechanism of cell death in AdCMV-*p53* infected SCCHN cell lines (Example 1). As noted above, the effect was more prominent for the Tu-138 cell line (mutated
20 *p53*) than it was for the MDA 686-LN cell line (wild-type *p53*). Growth curve assays were reproducible in three repeated studies without a significant difference being noted between the effect of the AdCMV-*p53* and the AdCMV-*p53*-FLAG viruses, suggesting that the addition of the FLAG peptide did not affect the ability of *p53* in suppression of cell growth.

25

Immunohistochemical Staining of SCCHN Cell Lines Infected with Adenovirus. Infected cell monolayers were compared for expression of the *p53* and *p53*-FLAG protein using standard immunohistochemical techniques. Neither the *p53* nor FLAG protein could be clearly identified in the mock infection of DL312 infected

-68-

cells in the MDA 686-LN cell line. However, in Tu-138, which has a mutated *p53* gene, endogenous staining for *p53* was positive. When cells were infected with the AdCMV-*p53* virus a strong staining was noted in both cell lines. Visual inspection of those cells infected with the AdCMV-*p53*-FLAG virus showed identical intensity of staining and number of positive cells with PAb1801 for antibody as compared to the cells infected with the AdCMV-*p53* virus. The cells infected with the AdCMV-*p53*-FLAG virus also showed strong immunohistochemical positivity with the M2 FLAG antibody. The quality of staining was different though, both within the nucleus and to a lesser degree in the cytoplasm.

***In Vivo* Suppression of Growth.** Dose response studies using 10^8 , 10^9 , and 10^{10} plaque forming units (pfu) of AdCMV-*p53*-FLAG virus compared to a control flap that was either PBS or DL312 were performed using the microscopic model method described in Example 1 on the Tu-138 cell line. The mean tumor size for the mock infection was $1205 \pm 205 \text{ mm}^3$. Tumor size decreased in a linear fashion with increasing concentration of virus used in the molecular intervention. Mean tumor size was $637 \pm 113 \text{ mm}^3$, $392 \pm 109 \text{ mm}^3$, and $193 \pm 74 \text{ mm}^3$ for those flaps treated with 10^8 , 10^9 , and 10^{10} pfu of the AdCMV-*p53*-FLAG respectively. Each animal was compared against itself using a paired t test and a significant dose response effect was noted at $p < 0.05$ in all comparisons except between the flap treated with 10^9 and 10^{10} pfu. Clearly, the greater the amount of virus, the greater the tumor growth inhibition visualized. In an additional study the effects of AdCMV-*p53* were compared to that of the AdCMV-*p53*-FLAG. No significant difference in activity was noted.

Immunohistochemical Demonstration of Exogenous Tumor Suppression Effect in the Microscopic Residual Disease Animal Model. After proving comparable *in vitro* and *in vivo* activity of the AdCMV-*p53* and the AdCMV-*p53*-FLAG, the inventor applied immunohistochemical techniques to demonstrate *p53*-

-69-

FLAG fusion protein product *in vivo*. Using the Tu-138 and MDA 686-LN cell lines, microscopic residual disease flaps were harvested 48 hours after treatment, fixed in formalin, and paraffin-embedded. On neighboring sections of tumor cells treated with the AdCMV-*p53*-FLAG virus, staining for both the *p53* and FLAG protein were
5 applied. Staining intensity and the number of cells staining positively was directly proportional to the amount of virus used in the infection. Controls were negative for staining with both *p53* and FLAG antibodies in the MDA 686-LN cells. Endogenous staining for *p53* was noted in the Tu-138 tumor cells. A histologic specimen stained with Hematoxylin and Eosin, the *p53* antibody, and the FLAG antibody. The
10 characteristic cytoplasmic staining with the FLAG M2 antibody contrasted with the intranuclear staining of the *p53* antibody. This is the first time that the FLAG M2 antibody has been proven to be effective on paraffin-embedded fixed tissue. The staining demonstrates that the tumor suppressive effect is directed by the exogenous therapy, and that in an *in vivo* model one can identify the exogenous therapy using the
15 applied FLAG system.

In conclusion, it is clear that the co-delivery of the FLAG protein along with the desired gene therapy offers potential utility as a marker of gene therapy. The invention clearly shows that it was simultaneously promoted along with the *p53* gene
20 and that expression of the messenger RNA and protein were not decreased. More importantly, the biologic activity of the delivered tumor suppressor gene was not altered. For the first time, the FLAG antibody was proven effective when immunohistochemical analysis was performed on formalin-fixed paraffin-embedded tissue. These factors suggest the utility of this novel protein as a tracer in further
25 gene therapy studies.

-70-

EXAMPLE 5**Treatment of Squamous Cell Carcinoma of the Head and Neck Using *p53*-
Adenovirus**

5

Patient A

A 53 year-old male patient presents with an inoperable SCCHN tumor of the head. The tumor mass is approximately 6.5 cm diameter. Following examination of bone marrow function, platelet count and renal function, the patient receives a first
10 treatment with 10^8 infectious particles of an adenovirus-*p53* expression construct, diluted in sterile phosphate buffered saline, via eight distinct intratumoral injections (total volume 10 ml). Every three days, the patient receives an identical treatment, until a total of six treatments have been given.

15

Three days after the sixth treatment, the tumor is examined and found to be > 4.0 cm in diameter. Histologic examination shows considerable cell fragmentation at the tumor margin. A second course of six treatments is undertaken, following which the tumor is found to be > 2.0 cm in diameter and necrotic. The patient continues to receive one a week treatments for three months, at which time the tumor is no longer
20 evident.

Patient B

A 44 year-old female patient presents with an operable SCCHN tumor of the neck. The tumor mass is approximately 2.5 cm diameter. Following examination of
25 bone marrow function, platelet count and renal function, the patient receives a first treatment with 5×10^7 infectious particles of an adenovirus-*p53* expression construct, diluted in sterile phosphate buffered saline, via three distinct intratumoral injections (total volume 3 ml). Every three days, the patient receives an identical treatment, until a total of six treatments have been given.

Three days after the sixth treatment, the tumor is excised. The tumor bed is bathed in 6 ml of sterile phosphate buffered saline for 60 min. The inoculum is removed, the wound closed, and a drain left in the tumor bed. On days 4, 7, 10 and 14 following surgery, 5×10^7 infectious particles of an adenovirus-p53 expression construct, diluted in sterile phosphate buffered saline (total volume 3 ml) are infused via the drain. After contacting the tumor bed for two hours, the inoculum is removed by suction. Sixth months following termination of treatment no primary, local or regional tumors are observed.

10

EXAMPLE 6

Wild-Type P53 Gene Transfer Via An Adenoviral Vector In A Phase I Trial Of Patients With Advanced Recurrent Head And Neck Squamous Carcinoma

15 An adenoviral vector containing the normal "wild-type" p53 gene was delivered in logarithmically increasing doses in patients with biopsy-confirmed recurrent squamous carcinoma of the head and neck. Direct tumoral injections were performed three times weekly for two consecutive weeks. Patients were stratified into two groups: 1) resectable recurrent disease, 2) unresectable recurrent disease.

20

Those patients stratified into the resectable disease group underwent total gross surgical resection of their recurrent neoplasm 72 hours following the sixth gene transfer events over a 2-week period. The adenoviral vector also was delivered intraoperatively and 72 hours following the surgical procedure via retrograde catheter infusion. Unresectable patients underwent repeat gene transfer attempts via direct tumoral injections monthly over two week cycles until disease progression or deterioration in patient performance status was observed. The safety of this treatment was monitored by close hospital observation, biopsies to assess gene transfer efficiency, bodily fluid analysis for shed vectors and necropsy analysis.

25

Methods

Study Subjects. Twenty-one patients with advanced recurrent squamous carcinomas of the upper aerodigestive tract with an Eastern Cooperative Oncology Group performance status 2 patients were entered into one of two study arms consisting of patients with resectable (Group 1) or non-resectable (Group 2) recurrent malignancies. The characteristics of the study subjects and dosage of adenoviral vector are shown in Tables 6 and 7, respectively. The women all had negative pregnancy tests and all patients used contraceptive methods. Informed consent was obtained from all patients prior to study entry.

Gene-Transfer Vector. The present study employed a replication-defective adenovirus serotype 5 vector with an enhancer (cytomegalovirus)-promoter designated Ad5CMVp53. Three lots of adenoviral vector with plaque-forming units (PFU) ranging from 10^9 to 10^{11} were produced by good manufacturing practices at Magenta, Inc. and Introgen Therapeutics, Inc. and shipped frozen (-70°C) to the University of Texas, M.D. Anderson Cancer Center. Each lot was efficacious for transduction utilizing western blotting as well as an *in vitro* tumor cell suppression growth assays. Vector was thawed and diluted in phosphate-buffered saline (vehicle) immediately prior to gene transfer and transported to patient rooms at 4°C .

TABLE 6
Patient Characteristics

Pt. No.	Age	Gender	Primary Cancer	Pathology	p53 genotype	Prior Failed Therapies	Site of Gene Transfer	*Study Arm
1	31	F	Floor of Mouth	Moderately diff. SCC	MAA	surgery, xrt, chemo	Facial mass	1
2	58	M	Larynx	Moderately diff. SCC	WT	surgery, xrt	Submental mass, nasopharynx	1
3	56	M	Pyriiform Sinus	Poorly differential	MAA	surgery, xrt	Left neck mass	2
4	42	F	Base of tongue	Poorly diff. SCC	WT	surgery, xrt	Right neck mass	2
5	71	M	Unknown	Poorly diff. SCC	WT	surgery, xrt, chemo	Left neck mass	1
6	43	M	Cervical, esophagus	Poorly diff. SCC	MAA	surgery, xrt, chemo	Peristomal mass	2

Table 6 continued:

Pt. No.	Age	Gender	Primary Cancer	Pathology	p53 genotype	Prior Failed Therapies	Site of Gene Transfer	*Study Arm
7	63	M	tonsil	Moderately diff. SCC	WT	xrt, chemo	Left neck mass	2
8	46	M	Base of tongue	Moderately diff. SCC	MAA	surgery, xrt	Base of tongue	1
9	57	M	Larynx	Well diff. SCC	WTT	surgery, xrt	Peristomal Recurrence	2
10	58	M	Larynx	Moderately diff. SCC	MAA	surgery, xrt	Hypopharyng eal mass	1
11	46	M	Base of tongue	Poorly diff. SCC	MAA	xrt, chemo	Base of tongue	1
12	57	F	Floor of mouth	Moderately diff. SCC	WT	surgery, xrt	Left retromolar trigone	2

Table 6 continued:

Pt. No.	Age	Gender	Primary Cancer	Pathology	p53 genotype	Prior Failed Therapies	Site of Gene Transfer	*Study Arm
13	66	M	Base of tongue	Moderately diff. SCC	WT	surgery, xrt	Posterior ora tongue & tongue base	2
14	48	F	Floor of mouth	Poorly diff. SCC	WT	surgery, xrt	Floor of mouth	2
15	63	M	Mandible alveolar ridg	Moderately diff. SCC	WT	surgery, xrt, chemo	Facial mass	2
16	76	F	Larynx	Poorly diff. SCC	MAA	xrt	Supraclavicular mass	1
17	56	M	Larynx	Moderately diff. SCC	WT	surgery, xrt, chemo	Base of tongue, tonsillar foss	2

Table 6 continued:

Pt. No.	Age	Gender	Primary Cancer	Pathology	p53 genotype	Prior Failed Therapies	Site of Gene Transfer	*Study Arm
18	56	M	L. Lateral pharyngeal wall	Moderately diff. SCC	WT	chemo	Facial neck mass	2
19	53	M	Unknown	Poorly diff. SCC	WT	surgery, xrt, chemo	Submental mass	1
20	55	M	Tongue	Poorly diff. SCC	WT	surgery, xrt, chemo	Neck mass	2
21	66	M	Base of tongue	Well diff. SCC	WT	chemo, xrt	Neck Mass	2

-77-

TABLE 7
Vector Dosing and Presence or Absence of Adenoviral Vector Nucleotides
in Serum or Urine During Treatment

Patient	PFU/ Transfer	Volume Injected	Gene Transfer Cycles	Site of Injections
1	10^6	6cc	2	Facial mass
2	10^6	3cc	2	Submental mass, neopharynx
3	10^6	3cc, 4cc	1	Left neck mass
4	10^6	3cc, 5cc	1 + 3	Right neck mass
5	10^6	1.5cc	1	Left neck mass
6	10^6	3cc	1	Peristomal mass
7	10^7	2cc	4 + 2	Left neck mass
8	10^7	3cc	1	Base of tongue mass
9	10^7	1.5cc	1	Peristomal recurrence
10	10^8	1.5cc	1	Hypo-pharynx mass
11	10^8	3cc	1	Base of tongue
12	10^8	1.5cc	3	Left retromolar trigone
13	10^9	1.5cc	6	R. Posterior tongue & tongue base
14	10^9	1.5cc	1 + 1	Floor of mouth
15	10^9	3cc	1	Left facial mass
16	10^9	1.5cc	1	L. Supraclavicular mass
17	10^9	1.5cc	1	Base of tongue, tonsillar fossa
18	10^9	3cc	4	Left facial mass
19	$10^{9.5}$	1.5cc	1	Submental mass
20	$10^{9.5}$	3cc	3	Left neck mass
21	$10^{9.5}$	1.5cc	3	Right neck mass

- 78 -

Dosage. The adenoviral vector was administered to five cohorts of patients each, and logarithmically increasing doses. Dosage increases were established following two weeks of observation of the last patient treated at the prior dose.

5 Following entry of the first six patients into the study, three patients were entered at each dosage level independent of the resectable or unresectable group the patient had been stratified to. The dose of biologic vector is described in terms of the total dose (in plaque-forming units). The estimated number of vectors administered per malignant epithelial cell was not approximated. The total volume of administration is

10 shown in Table 7. The volume of adenoviral vector injected into the solid malignancies was determined by the clinical and radiographic estimated tumor volume. The vector was directly injected into the recurrent squamous carcinomas under direct vision and by manual palpation. Injections were spaced at 1 centimeter increments across masses. After gene transfer, the subject remained under close

15 observation for at least 1-1/2 hours. Respiratory and body secretion isolation were maintained for 72 hours following the final gene transfer of vector.

Detection of Vector. The urine and serum samples were monitored for disseminated adenoviral vector utilizing viral culture of 293 cells as well as

20 polymerase chain reactions (PCR) using primers that amplify the E1b region of the adenovirus and the 5' end of the wild-type p53 gene which were specific to the vector. PCR products were then southern transferred to improve viral detection to 1-5 viral particles as well as verify PCR product specificity. Positive and negative controls were assayed in each reaction.

25

Safety. The symptoms, vital signs, blood counts were monitored, and the patients were physically examined and photographically documented daily. Chest radiography, blood chemistry testing, and performance status analysis were performed at the beginning of each treatment cycle. Serum titers of adenoviral antibody were

30 measured before and following each cycle of gene transfer. Three days following the

- 79 -

sixth gene transfer of the first cycle, tumor biopsies (or surgical resection) were obtained. Specimens were stored as snap-frozen, pathologically embedded specimens, as well as formalin-fixed specimens in every instance.

5 **Extraction of Nucleic Acids from Serum or Urine.** Ad5CMV-p53 adenoviral DNA was extracted from 0.5-ml aliquots of serum or urine by a method modified from Cunningham *et al.*, (1995). Briefly, distilled water was added to make 1 ml, and they were precipitated with 30% polyethyleneglycol (PEG). Since SDS alone was not sufficient to release the viral DNA from its particle, proteinase K was
10 added to the SDS at 50°C for 2-16 hours following the PEG precipitation (Norder *et al.*, 1990). The samples were extracted with phenol, and viral DNA was precipitated with ethanol in the presence of glycogen (Cunningham *et al.*, 1995).. The precipitated DNA was recovered by centrifuging at 14000 g for 10 minutes at 4°C, resuspended in 0.3 ml of distilled water, and reprecipitated with ethanol. The DNA pellet was rinsed
15 with 70% ethanol, vacuum-dried, and dissolved in 10 µl of distilled water. Samples were either analyzed immediately or stored at -20 until used. Extraction of nucleic acids was performed under biologic safety cabinet hoods to prevent possible cross-contamination of specimens.

20 **PCR Reactions on DNA Isolated from Serum Samples.** Primers were designed for specific amplification of the p53 gene from the adenoviral vector. The upper primer (5'-CACTGCCCAACAACACCA-3', SEQ ID NO:5) corresponds to the 3' end of the p53 gene and the lower primer (5'-GCCACGCCCACACATTT-3' SEQ ID NO:6) corresponds to the E1B region of adenovirus type 5 (nucleotides 3517 to
25 3533 of the wild-type sequence). Each PCR reaction tube contained 0.2 mM of each oligonucleotide, 0.4 mM dNTPs, 1X TaqPlus Long low salt buffer (from Stratagene), 0.6 µl TaqPlus Long (5U/ml) (from Stratagene), and 5 µl of test DNA. The samples were placed in an MJ Research Peltier Thermal Cycler (PTC-200) programmed for 93°C for 3 minutes, with the following three-step profile: 93°C for 30 seconds, 65°C

- 80 -

for 45 seconds and 72°C for 45 seconds for a total of 30 or 35 cycles. 5 ul of 6X loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF and 15% Ficoll (Type 400; Pharmacia) in water) was added to each tube at the end of the PCR run and loaded onto a 1% agarose, 1X TBE gel containing ethidium bromide (.6 µg/ml). The samples were electrophoresed at 100V for 1-1.5 hours and then photographed under UV light.

Polymerase Chain Reaction (PCR). Only 5 µl of prepared DNA could be used in a single polymerase chain reaction. For serum, the PCR was performed in a 20-µl volume containing 2 mM MgCl₂, 50 mM KCl, 0.1% Triton X-100, 200 µM each of deoxyribonucleoside triphosphates (dNTP), 10 mM Tris-HCl (pH 9.0), 5 µM each of the primers, and 1.7 units of *Taq* DNA polymerase (Promega). The reactions were carried out at 94°C for 30 sec, 58°C for 30 sec, and 72°C for 60 sec for 35 cycles, followed by a 10-min extension at 72°C. The PCR primers were selected from the sequence of the Ad5CMV-p53 with the sense primer located at the 3' end of the p53 cDNA (5'-GCCTGTCCTGGGAGAGACCG-3', SEQ ID NO:7), and the antisense primer was selected from the E1B region of adenovirus type 5 (5'-CCCTTAAGCCACGCCCACAC-3', SEQ ID NO:8). The PCR product (an 838-bp fragment) was separated on 1% agarose gel. The same PCR product was subcloned into pCR-Script vector (Stratagene), sequenced, and the gel purified insert was used as a probe to detect the PCR product. For urine, the PCR was performed in a 20-µl volume containing 2 mM MgSO₄, 10 mM (NH₄)₂SO₄, 10 mM KCl, 0.1% Triton X-100, 20 mM Tris-HCl (pH 8.8), 0.1 mg/ml bovine serum albumin, 200 µM each of deoxyribonucleoside triphosphates (dNTP), 5 µM each of the primers, and 2.5 units of *TaqPlus* long DNA polymerase (Stratagene). The reactions were carried out at 93°C for 60 sec, and then 93°C for 30 sec, 65°C for 45 sec, and 72°C for 45 sec for 35 cycles, followed by a 10-min extension at 72°C. The PCR primers were selected from the sequence of the Ad5CMV-p53 with the sense primer located at the 3' end of the p53 cDNA (5'-CACTGCCCAACAACACCA-3', SEQ ID NO:9), and the antisense

- 81 -

primer was selected from the E1B region of adenovirus type 5 (5'-GCCACGCCCCACACATTT-3', SEQ ID NO:10). The PCR product (an 724-bp fragment) was separated on 1% agarose gel.

5 **Southern Blot Analysis.** In the Southern blot used to verify the PCR product's specificity, the DNA in the gel was denatured and neutralized before blotting to nylon membrane (Hybond-N+, Amersham) by capillary absorption. The membrane was prehybridized for 15 min at 65°C in Rapid-hyb buffer (Amersham) and hybridized in the same buffer containing ³²P-labeled probe for 1-2 h. The
10 membrane was washed in 0.1 x SSC and 0.1% SDS at room temperature twice, and again twice at 65°C (15 min per wash). The washed membrane was exposed to x-ray film at -70°C for 1-16 h with intensifying screen.

Controls and scoring of test samples. The following controls were included
15 with every batch of samples. At the DNA isolation step, two "negative" serum controls (pooled and aliquoted serum from Introgen employees), and two positive controls consisting of negative serum spiked with 10pfu or 100 pfu of AdCMV-p53 virus were employed. This was done to obtain a window of sensitivity where the 10 (and 100) pfu controls were positive, but the negative controls were negative. If the
20 negative controls were positive, the PCR was repeated with only 30 cycles. If the 10 pfu control was negative, the DNA was further purified with an additional ethanol precipitation, and the PCR was repeated. The above two steps always placed the experimental parameters into the appropriate sensitivity window.

25 At the PCR stage, a positive control of 1 ng of AdCMV-p53 DNA (isolated from a clinical lot), and a negative (H₂O) control were employed. The PCR of the batch was repeated if any of the controls were false. There were no failed negative PCR controls.

- 82 -

For confirmation of putative positives, the DNA was re-isolated from serum (along with several temporally adjacent samples), and the PCR of this DNA repeated.

Samples were scored as positive only if the results could be reproduced. Those samples which were positive in one of two sample analyses were considered negative
5 for reporting purposes. Putative positives that could not be repeated (due to lack of further unprocessed specimen) were omitted from the database.

Measuring Efficacy of Gene Transfer. Surgically removed tissue specimens were placed in cryovials, immediately flash frozen, and then stored in liquid nitrogen
10 storage until use. Frozen samples were decanted into the orifice of a stainless steel Bessman tissue pulverizer (Spectrum, Houston, TX) that had been pre-cooled by immersion in liquid nitrogen. Tissue was crushed to a fine powder by striking the Bessman pestle with a steel hammer five to ten times. Pulverized tissue was transferred to a glass tissue homogenizer (Fisher Scientific, Pittsburgh, PA)
15 containing 1 ml TRI reagent (Molecular Research, Cincinnati, OH) per 50 mg tissue, and homogenized by five to ten up and down strokes with a Teflon pestle.

Following homogenization, RNA was isolated according to the instructions provided with the TRI reagent. Briefly, homogenates were transferred to
20 polypropylene centrifuge tubes (Molecular Research) and stored for 5 min at room temperature prior to the addition of chloroform (0.2 ml per 1 ml of TRI reagent). Samples were then mixed vigorously, incubated an additional 15 min at room temperature, and centrifuged at 12,000 x g for 15 min at 4°C to separate the RNA containing aqueous layer from the phenol-chloroform phase. Isopropanol was added
25 to the aqueous phase and RNA was precipitated by incubating at room temperature for 15 min. RNA pellets were recovered by centrifugation at 12,000 x g for 15 min at 4°C, washed once with 75% ethanol, air dried, dissolved in diethyl pyrocarbonate (DEPC)-treated water and quantitated by measuring the absorbance at 260 nm. Contaminating DNA was removed by incubating up to 50 µg RNA with 60 U DNase

- 83 -

I (Pharmacia, Piscataway, NJ) for 25 min at 37°C in a total reaction volume of 260 µl. RNA was then extracted with phenol:chloroform, ethanol precipitated, washed once with 75% ethanol, pelleted by centrifugation at maximum speed in a microfuge for 15 min at 4°C, air dried, resuspended in DEPC-water, and stored at -80°C. The quality of
5 RNA was assessed by running samples on an ordinary non-denaturing 0.8% agarose gel and visualizing the 28S and 18S ribosomal bands by ethidium bromide staining. To eliminate cross-contamination between samples and to minimize RNase activity, all re-usable instruments employed for RNA isolation were soaked in a 2% Liqui-Nox (Fisher Scientific) detergent solution for a minimum of 5 minutes, scrubbed free of
10 debris, transferred to a 10% bleach solution for 3 minutes, rinsed thoroughly with deionized water, sprayed with 100% ethanol, dried, immersed in chloroform, and dried again before use.

Reverse transcription was performed using 1.5 µg total cellular RNA in a 23.5
15 µl reaction mix containing 111 ng random hexamers (Gibco BRL, Grand Island, NY), 40 units RNase inhibitor (Boehringer Mannheim, Indianapolis, IN), 0.4 mM of each dNTP (Perkin Elmer, Foster City, CA), and 300 units of Superscript II RNase H⁻ reverse transcriptase (Gibco BRL) in 1 x RT buffer (50 mM Tris pH 8.3, 75 mM potassium chloride, 3 mM magnesium chloride, and 20 mM dithiothreitol). RNA and
20 random hexamers were heated to 70°C for 10 min and cooled on ice before the rest of the reaction mix was added. The reaction was incubated at 25°C for 5 min with 200 units reverse transcriptase, and then an additional 10 min at 25°C following addition of another 100 units reverse transcriptase, to facilitate primer annealing, before incubating at 42°C for 50 min. The RT-reactions were terminated by heat inactivating
25 the reverse transcriptase for 15 min at 70°C. RNA complementary to cDNA was removed by digestion with 1 unit RNase H (Boehringer Mannheim) for 20 min at 37°C. RNA from the head and neck squamous cell carcinoma (HNSCC) line TU167 infected with recombinant adenovirus Ad5CMV-*p53* (multiplicity of infection of 100:1) was used as a positive control for detecting virally transcribed *p53*, and TU167

- 84 -

cells infected with the variant adenovirus vector dl312 (1) that does not contain the p53 transcriptional unit was used as a negative control.

To detect the Ad5CMV-*p53* transcript, PCR was performed in a reaction
5 volume of 30 µl containing 0.2 mM of each dNTP, 1.5 mM magnesium chloride, 1
unit taq polymerase (Promega, Madison, WI), and 0.5 mM of each primer CMV2 (5'
GGTGCATTGGAACGCGGATT, SEQ ID NO: 11) and P53EX3 (5'
GGGGACAGAACGTTGTTTTC, SEQ ID NO:12) in 1 x PCR buffer (50 mM
potassium chloride, 10 mM Tris pH 9.0, 0.1% Triton X-100). Primers CMV2 and
10 P53EX3 amplify a 295-base fragment specific to the adenovirus derived p53
transcript. PCR conditions for detecting Ad5CMV-*p53* transcripts were as follows:

94°C for 1 min, followed by 94°C for 30 sec, 58°C for 40 sec, 70°C for
1 min for 35 cycles, and 70°C for 10 min extension time.

15

To ensure that the product amplified during PCR was detecting mRNA and
not contaminating DNA in the RNA preparation, PCR was also performed using RT
products from parallel reactions in which no reverse transcriptase was added.

20 RT-PCR specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was performed in order to check the integrity of the RT reactions. A 3 µl volume of
the RT reaction was diluted in 30 µl of PCR mix containing 0.2 mM of each DNTP, 2
mM magnesium chloride, 1 unit taq polymerase, and 0.5 mM of each primer
GAPDH1 (5' ACGGATTTGGTCGTATTGGG, SEQ ID NO:13) and GAPDH2
25 (5' TGATTTTGGAGGGATCTCGC, SEQ ID NO:14) in 1 x PCR buffer. The
GAPDH primers span 3 exons in the human GAPDH gene and amplify a 231-base
product specific for mRNA. PCR conditions to detect GAPDH were as follows:

- 85 -

94°C for 1 min, followed by 94°C for 30 sec, 60°C for 12 sec, 72°C for 1 min for 35 cycles, and 72°C for 7 min extension time.

5 PCR was performed using a Perkin Elmer Gene Amp 9600 thermocycler, and all primers were commercially synthesized (Genosys, Woodlands, TX).

Immunohistochemical Determination of Intratumoral Gene.

Immunoperoxidase studies were performed on formalin-fixed, paraffin-embedded tissue sections using the avidin-biotin-peroxidase complex (ABC) method (1). The
10 specimens were cut 3-4µm thick, deparaffinized in xylene, and rehydrated in descending grades (100-70%) of ethanol. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol. After several washes in distilled water and phosphate buffered saline (PBS), section were incubated with a 1:10 dilution of normal horse serum to minimize background staining. This was followed
15 by overnight incubation at 4°C with monoclonal antibodies to p53 (DO-1, Oncogene Science, Inc., Uniondale, NY; 1:80 dilution) and p21 (Oncogene Science, Inc., 1:100). Peroxidase staining procedure was done using ABC Elite kits (Vector Laboratories, Burlingame, CA). The immunostaining reaction was visualized using 0.05% 3,3'-diaminobenzidine in Tris-HCl buffer containing 0.01% hydrogen peroxide, pH 7.6.
20 Sections were counterstained with 0.01% toluidine blue and mounted in permount. Scoring was performed by counting positive nuclear staining in 200 cells of 10 consecutive high power fields by two independent observes.

TUNEL Assay for DNA Fragmentation. The TUNEL assay was performed
25 using the ApoptagTM PLUS kit (Oncor, Gaithersburg, M.D.) according to instructions provided by the manufacturer. Slides were counterstained with .4% methylene green. Corresponding hematoxylin and eosin stained slides were evaluated for the presence of inflammatory cell infiltrates and were graded on a scale of 1-4.

- 86 -

Cytopathic Effect Assay Procedure. Patient urine samples also were monitored for the presence of Ad5p53 by an assay in which any virus in the sample is allowed to infect a recipient cell monolayer. Those cells are monitored for the appearance of a cytopathic effect (CPE): the cells round up and detach from the surface. The patient urine samples assayed for CPE were from the first morning urines collected during the second week of the first treatment course, and on Day 0 or 1 (pretreatment). Samples of approximately 15 mls each were stored in sterile 15-ml conical tubes at -80°C until use. The IT293 cells, which form the recipient cell monolayer in this assay, are maintained in DMEM plus 10% FBS, in a 37°C humidified 10% CO₂ incubator. Two days prior to patient sample testing, the cells were plated at 2×10^5 per well in 12-well plates.

At time of assay, the urine samples were thawed in an ice bath, and an aliquot was mixed 1:1 with DMEM and sterile-filtered using a 0.22 µm syringe filter. A 350 µl aliquot of this 1:1 mix was slowly added to each well after removing the growth medium. The plate was gently rocked 15 minutes later. After 30 minutes, 2.0 ml of DMEM plus 10% FBS was added to each well to dilute the sample. On day 3 (72 hours later) and day 6 of the assay, 0.5 ml aliquots of fresh medium were added to each well, to help maintain the cell monolayer for the maximum 6-7 days.

Patients samples were assayed in triplicate. The diluted pretreatment sample was assayed as is, and also spiked with 10^5 pfu of Ad5p53 per well to detect any urine component that might interfere with the detection of virus by this procedure. Control wells were inoculated with DMEM alone spiked with 10^5 , 10^4 , 10^3 , 10^2 , or 10^1 pfu per well, each in duplicate. The 10^5 pfu spike causes CPE under these conditions on day 2 of the assay; on each successive day, the next spiked control will show CPE. Therefore, the time at which CPE is detected in each patient sample indicates the level of Ad5p53 in that sample.

- 87 -

Recombinant Competent Adenovirus. The adenoviral p53 used in the clinical trial was tested for the presence of RCA using A549 cells by the Biotechnology Services Division of Microbiological Associates, Inc., (Rockville, Maryland).

5

Statistical Analysis. A single-arm study design was used. To prevent enrolling more patients than necessary in a trial of excessive toxicity was found, a Bayesian early stopping rule was implemented. The WILCOXON signed rank test and assigned test were used for comparisons between before and after treatment of the percentage of cells showing TUNEL and immunohistochemical staining, respectively. Statistical analysis was performed using the Survpac SPSS-Statistical package.

Response and Toxicity. Survival and response were assessed in this interim analysis, but were not considered aims of this analysis. The purpose of this interim analysis was to determine transduction potential of this gene transfer strategy. Patients were evaluable for response and toxicity following a 30-day observation after one cycle of gene transfer. Toxic effects of therapy were evaluated according to the National Cancer Institute's common toxicity criteria. (Xref.) Response to therapy was assessed by CT scan or ultrasound of the neck before each course of treatment. Patients were evaluable for response if they received at least one course of therapy followed by an appropriate documentation of response. Those patients undergoing surgical resection of their recurrent tumors could not be evaluated for response since surgery was performance prior to a 30 day observation period. All CT scans were evaluated by one radiologist and ultrasounds by another. Partial response was defined as a 50 percent or greater reduction in the sum of the products of the diameters of the measureable tumor; a minor response was defined as a 25 percent to less than 50 percent reduction in the sum of the products of the diameters of the measureable lesion. Progression of disease was defined as a 25 percent or greater increase in the sum of the products of the diameters.

Survival duration was measured from time of protocol entry until expiration. Each patient's response was reviewed by a data management committee consisting of a Head and Neck Surgical Oncologist, Radiologist, and Medical oncologist.

5

Results

Detection of Vector. Adenoviral-vector DNA was detected by PCR in serum as well as urine samples from patients up to 48 hours following gene transfer. The detection limit for vector is 1-5 viral particles. Viral DNA was isolated in urine among patients undergoing gene transfer at each viral dosage, but not detected after 48 hours following gene transfer. Serum detection of viral DNA increased with increasing viral dosage above 10^7 PFU, but was also not detectable 48 hours following gene transfer.

Urine samples were first analyzed for infectious virus, measured CPE on cell monolayers, prior to PCR nucleotide analysis. The virus present in the urine was applied to 293 cells as described above, in order to monitor the CPE, which is observed as the cells round up and become from the petri dish. CPE was identified rarely in specimens. CPE was found late in overlay cultures (greater than six days) and these results were considered equivocal. In no instance was CPE confirmed by PCR and Southern blot transfer of the same urine sample for detected adenoviral nucleotides.

Viral DNA Analysis of other Organ Systems. PCR analysis demonstrated viral DNA greater than two months following 10^9 Ad5CMVp53 gene transfer in skin, cardiac muscle, lung, and testicular tissues in snap frozen autopsy specimens carefully sampled to prevent cross-contamination between tissues. Renal parenchyma, adrenal glands and pancreatic tissues did not show viral DNA sequences specific for this

- 89 -

vector. Immunohistochemical analysis of these autopsy specimens (did not reveal evidence of wild-type p53 protein product overexpression).

Assessment of Gene Transfer. All analyses were performed after at least 1 hour of exposure of tissues to the vector. The mRNA product was detected at 4 hours and 48 hours via RT-PCR. In contrast, biopsy specimens frozen after 1 hour of exposure or less, showed no *p53* mRNA. In addition, negative control samples obtained from an operative site that had not been subjected to gene transfer were also negative for the PCR product. Non-transduced and transduced biopsy specimens from four patients were analyzed by RT-PCR for the presence of Ad5CMVp53 transcribed mRNA. Transduced specimens from two patients were positive on EtBr stained gels, while no Ad5CMVp53 product was detected in any of the non-transduced specimens despite the fact that GAPDH could be amplified from all specimens. The specificity of the 295 bp PCR product from the two positive patients was confirmed by Southern Blotting. Because PCR product was not observed when reverse transcriptase was omitted from the RT reactions, the 295 bp product detected in the figure had to have been generated from mRNA, rather than contaminating DNA.

Immunohistochemical Analysis. All patients pre- and post-gene transfer specimens were simultaneously analyzed with positive and negative controls in each experiment. Multiple sections of each specimen were analyzed and compared with hematoxylin and eosin-stained as well as TDT end-labeled specimens. Post-vector injected biopsy specimens confirmed gene transfer in three patients whose pre-transfer biopsy specimens did not show endogenously overexpressed p53 protein. In 5 of 21 patients (27%), p21 (CIP/WAF1) was not significantly endogenously expressed; this proved informative for gene transfer in the patient post-gene transfer biopsy specimens. p53 nuclear protein overexpression was also seen in tumor-

- 90 -

associated lymphocytes as well as stromal tumor cells, thus indicating nontumor cell transduction as well.

Serologic Antibody Response. Adenovirus serotype 5 antibodies were induced in all patients following repeat injections of the vector. However, transduction efficiency was not found to be significantly altered comparing the initial cycle of gene transfer and subsequent cycles. Mild tumor injection site erythema was recognized beginning at 3×10^9 PFU., however these local reactions did not limit vector tolerance. No evidence of systemic hypersensitivity was found in any patients despite repeat viral dosing for as much as six consecutive months in a 10^9 PFU-treated patient.

Pathologic Observations. Needle tracks have been identified in the majority of biopsy specimens, and gene product expression was demonstrated in deeper tissues beyond the injection sites. Similarly, the finding of end-labeled cells in transduced areas suggested the induction of apoptosis in tumor cells but the absence of apoptosis in stromal or inflammatory cells. Inflammatory cells were noted in patients and became prominent histologic findings among the patients who received doses of 10^9 PFU or greater. Interestingly, patient number 7, whose sampled expressed endogenous wild-type p53, demonstrated hemorrhagic necrosis with no evidence of viable tumor in serially sectioned surgical specimens in his recurrent 2 cm neck mass after one-cycle of gene transfer. Pathologic findings of necrosis as well as apoptosis induction were frequent observations in specimens.

Clinical Observations. Patients have tolerated direct tumoral injections of vector with the most frequent adverse event being injection site discomfort. Evidence of local injection site erythema has been noted at 10^9 PFU of vector and higher although systemic evidence of hypersensitivity has not been seen despite evidence of systemic antibody titer elevations. Patients number 5, 10, and 16

remain without evidence of disease with a median follow-up of seven months. Patients 7 and 13 exhibited stable disease for 3 and 5 months, respectively in their indicator lesion area. Patient number 20 exhibited a partial response as verified by CAT Scan and ultrasound, but developed spinal and pleural metastasis requiring
5 removal from study due to disease progression.

In conclusion, patients with recurrent squamous carcinomas of the head and neck, adenovirally mediated gene transfer of wild-type *p53* is safe and can effectively transduce cancer and normal cells via direct tumoral injections or
10 intraoperative instillation of vector. None of the patients exhibited toxicity that might limit vector administration or dose escalation. Transgene product expression was unaltered despite development of a systemic antibody response. The local inflammatory responses found pathologically within resected tumor specimens may, in fact, be beneficial.

15

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a
20 stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.



- 92 -

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated
5 herein by reference:

"Cancer facts and figures," American Cancer Society, Washington, DC: ACS,
(Publication no. 90-425 M. no. 5008-LE).1990.

- 10 Cancer Facts and Figures, Publication No 93-400, M No. 5008-93. Washington, DC:
American Cancer Society, 1993.

Anderson *et al.* US 5,399,346, 1995.

- 15 Baichwal and Sugden, "Vectors for gene transfer derived from animal DNA viruses:
Transient and stable expression of transferred genes," *In*: Kucherlapati R, ed.
Gene transfer. New York: Plenum Press, pp. 117-148, 1986.

- Baker *et al.*, "Suppression of human colorectal carcinoma cell growth by wild-type
20 *p53*," *Science*, 249:912-915, 1990.

Barbacid, M. "*ras* genes," *Ann. Rev. Biochem.*, 56:779-827, 1985.

- Bartek *et al.*, "Genetic and immunochemical analysis of mutant *p53* in human breast
25 cancer cell lines," *Oncogene*, 5:893-899, 1990.

Benvenisty and Neshif, "Direction introduction of genes into rats and expression of
the genes," *Proc. Nat'l Acad. Sci. USA*, 83:9551-9555, 1986.

- 93 -

- Berenson *et al.*, "Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas," *Oncogene*, 4:1111-1116, 1989.
- 5 Berges *et al.*, "Cell proliferation, DNA repair, and *p53* function are not required for programmed cell death of prostatic glandular cells induced by androgen ablation," *Proc. Natl. Acad. Sci. USA*, 90:8910-8914, 1993.
- 10 Berkner, "Development of adenovirus vectors for the expression of heterologous genes," *BioTechniques*, 6:616-629, 1988.
- Bos, J., "*ras* oncogenes in human cancer: A review," *Cancer Res.*, 49:2682, 1989.
- 15 Boshart *et al.*, "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus," *Cell*, 41:521-530, 1985.
- Boussif *et al.*, "A versatile vector for gene and oligonucleotide transfer into cells in culture and *in vivo*: Polyethylenimine," *Proc. Natl. Acad. Sci. USA*, 92:7297-7301, 1993.
- 20 Boyle *et al.*, "The Incidence of *p53* Mutation Increases with Progression of Head and Neck Cancer," *Can Res.*, 53:4477-4480, 1993.
- Brennan *et al.*, "Molecular Assessment of Histopathological Staging in Squamous-Cell Carcinoma of the Head and Neck," *NEJM*, 332(7):429-425, 1995.
- 25 Brown *et al.*, "Modulation of *ras* Expression by Anti-sense, Nonionic Deoxyoligonucleotide Analogs," *Oncogene Res.*, 4:243-252, 1989.

- 94 -

- Cai *et al.*, "Stable expression of the wide-type *p53* gene in human lung cancer cells after retrovirus-mediated gene transfer," *Human Gene Therapy*, 4:617-624, 1993.
- 5 Calhoun *et al.*, "Distant Metastases from Head and Neck Squamous Cell Carcinomas," *Laryngoscope*, 104:1199-1205, 1994.
- Campbell, in *Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology Vol. 13*, Burden and Von Knippenberg, Eds. pp. 75-83, Amsterdam, Elsevier, 1984
- 10
- Chen *et al.*, "Genetic mechanisms of tumor suppression by the human *p53* gene," *Science*, 250:1576-1580, 1990.
- 15 Chen and Okayama, "High-efficiency transfection of mammalian cells by plasmid DNA," *Mol. Cell Biol.*, 7:2745-2752, 1987.
- Chomczynski and Sacchi, "Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction," *Anal. Biochem.*, 162:156-159, 1987.
- 20
- Chung *et al.*, "Discordant *p53* gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract," 53:1676-1683, 1993.
- 25
- Clarke *et al.*, "Thymocyte apoptosis induced by *p53*-dependent and independent pathways," *Nature*, 362:849-852, 1993.

- 95 -

- Clayman *et al.*, "Regulation of Urokinase-Type Plasminogen Activator Expression in Squamous-Cell Carcinoma of the Oral Cavity," *Int J Cancer*, 54:73-80, 1993.
- 5 Couch *et al.*, "Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract," *Am. Rev. Resp. Dis.*, 88:394-403, 1963.
- Culver *et al.*, "*in vivo* gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," *Science*, 256:1550-1552, 1992.
- 10 Debus *et al.*, "Effects of Antisense Oligodeoxyribonucleotides Complementary mRNA of the Human *c-Harvey-ras* Oncogene on Cell Proliferation," *J. Cancer Res. Clin. Oncol.*, 116 (Suppl. Part 1):S-162, 1990.
- Der and Cooper, *Cell*, 32:201-8, 1983.
- 15 Diller *et al.*, "*p53* function as a cell cycle control protein in osteosarcomas," *Mol. Cell. Biol.*, 10:5772-5781, 1990.
- Donehower *et al.*, "Mice deficient for *p53* are developmentally normal but susceptible to spontaneous tumors," *Nature*, 356:215-221, 1992.
- 20 Dubensky *et al.*, "Direct transfection of viral and plasmid DNA into the liver or spleen of mice," *Proc. Nat'l Acad. Sci. USA*, 81:7529-7533, 1984.
- 25 El-Deiry *et al.*, "WAF1/CIP1 is induced in *p53*-mediated G₁ arrest and apoptosis," *Cancer Res.*, 54:1169-1174, 1994.
- Fearon *et al.*, *Science*, 247:49, 1990.

- 96 -

- Fechheimer *et al.*, "Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading," *Proc. Nat'l Acad. Sci. USA*, 84:8463-8467, 1987.
- 5 Ferkol *et al.*, *FASEB J.*, 7:1081-1091, 1993.
- Field *et al.*, "Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma," *Oncogene*, 4:1463-1468, 1989.
- 10 Field *et al.*, "The Role of the *p53* Tumor Suppressor Gene in Squamous Cell Carcinoma of the Head and Neck," *Arch Otolaryngol Head Neck Surg*, 119:1118-1122, 1993.
- 15 Fraley *et al.*, "Entrapment of a bacterial plasmid in phospholipid vesicles: Potential for gene transfer," *Proc. Nat'l Acad. Sci. USA*, 76:3348-3352, 1979.
- Fridman *et al.*, "The minimal fragments of c-Raf-1 and NF1 that can suppress a v-Haras-induced phenotype," *J. Biol. Chem.*, 269:30105-30108, 1994.
- 20 Friedmann, "Progress toward human gene therapy," *Science*, 244:1275-1281, 1989.
- Fujiwara *et al.*, "Therapeutic effect of a retroviral wild-type *p53* expression vector in an orthotopic lung cancer model," *JNCI*, 86:1458-1462, 1994.
- 25 Fujiwara *et al.*, "A retroviral wild-type *p53* expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis," *Cancer Res.*, 53:4129-4133, 1993.

- Gefter *et al.*, Somatic Cell Genet. 3:231-236 (1977)
- 5 Georges *et al.*, "Prevention of Orthotopic Human Lung Cancer Growth by Intratracheal Instillation of a Retroviral Antisense K-ras Construct," *Cancer Res.*, 53:1743-1746, 1993.
- 10 Ghosh-Choudhury *et al.*, "Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full-length genomes," *EMBO J.*, 6:1733-1739, 1987.
- 15 Ghosh and Bachhawat, "Targeting of liposomes to hepatocytes," *In*: Wu G. and C. Wu ed. Liver diseases, targeted diagnosis and therapy using specific receptors and ligands. New York: Marcel Dekker, pp. 87-104, 1991.
- 20 Goding, 1986, in Monoclonal Antibodies: Principles and Practice, 2d ed., Orlando, Fla., Academic Press, 1986, pp. 60-61, 65-66, 71-74.
- 25 Gomez-Foix *et al.*, "Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen," *J. Biol. Chem.*, 267:25129-25134, 1992.
- 30 Gopal, "Gene transfer method for transient gene expression, stable transfection, and cotransfection of suspension cell cultures," *Mol. Cell Biol.*, 5:1188-1190, 1985.
- 35 Gorczyca *et al.*, "Detection of DNA strand breaks in individual apoptotic cells by the *in situ* terminal deoxynucleotidyl transferase and nick translation assays," *Cancer Res.*, 53:1945-1951, 1993.

- Graham and Prevec, "Adenovirus-based expression vectors and recombinant vaccines," *Biotechnology*, 20:363-390, 1992.
- 5 Graham and Prevec, "Manipulation of adenovirus vector," *In*: E.J. Murray (ed.), *Methods in Molecular Biology: Gene Transfer and Expression Protocol*, Clifton, NJ: Humana Press, 7:109-128, 1991.
- 10 Graham *et al.*, "Characteristics of a human cell line transformed by DNA from human adenovirus type 5", *J. Gen. Virol.*, 36:59-72, 1977.
- Graham and van der Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA", *Virology*, 52:456-467, 1973.
- 15 Grunhaus and Horwitz, "Adenovirus as cloning vector," *Seminar in Virology*, 3:237-252, 1992.
- 20 Harland and Weintraub, "Translation of mammalian mRNA injected into *Xenopus* oocytes is specifically inhibited by antisense RNA," *J. Cell Biol.*, 101:1094-1099, 1985.
- Hartwell and Kastan, "Cell cycle Control and Cancer," *Science*, 266:1821-1828, 1994.
- 25 Hermonat and Muzycska, "Use of adenoassociated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells," *Proc. Nat'l Acad. Sci. USA*, 81:6466-6470, 1984.

- 99 -

- Herz and Gerard, "Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice," *Proc. Nat'l Acad. Sci. USA* 90:2812-2816, 1993.
- 5 Hoollstein *et al.*, "*p53* mutations in human cancers," *Science*, 253:49-53, 1991.
- Hopp *et al.*, "A Short Polypeptide Marker Sequence Useful for Identification and Purification of Recombinant Proteins," *BioTechnology*, 7:1205-1210, 1988.
- 10 Hsu *et al.*, "Use of Avidin-Biotin-Peroxidase Complex (ABC) in Immunoperoxidase Techniques: a Comparison Between ABC and Unlabeled Antibody (PAP) Procedures," *J. Histochem. Cytochem.*, 29:577-580, 1981.
- Jones and Shenk, "Isolation of deletion and substitution mutants of adenovirus type
- 15 5," *Cell*, 13:181-188, 1978.
- Kaneda *et al.*, "Increased expression of DNA cointroduced with nuclear protein in adult rat liver," *Science*, 243:375-378, 1989.
- 20 Karlsson *et al.*, *EMBO J.*, 5:2377-2385, 1986.
- Kashani-Sabet *et al.*, "Reversal of the malignant phenotype by an anti-*ras* ribozyme," *Antisense Res. Dev.*, 2:3-15, 1992.
- 25 Kastan *et al.*, "A mammalian cell cycle checkpoint pathway utilizing *p53* and GADD45 is defective in ataxia-telangiectasia," *Cell*, 71:587-597, 1992.
- Kato *et al.*, "Expression of hepatitis B virus surface antigen in adult rat liver," *J. Biol. Chem.*, 266:3361-3364, 1991.

- 100 -

- Klein *et al.*, "High-velocity microprojectiles for delivering nucleic acids into living cells," *Nature*, 327:70-73, 1987.
- 5 Kohler and Milstein, *Eur. J. Immunol.*, 6:511-519, 1976.
- Kohler and Milstein, *Nature*, 256:495-497, 1975.
- Kozarsky and Wilson, "Gene Therapy: Adenovirus Vectors," *Curr. Opin. Genet. Dev.*,
10 3:499-503, 1993.
- Kyte and Doolittle, "A simple method for displaying the hydropathic character of a protein," *J. Mol. Biol.*, 157(1):105-132, 1982.
- 15 Lane and Crawford, "T antigen is bound to a host protein in SV40-transformed cells,"
Nature, 278:261-3, 1979.
- Le Gal La Salle *et al.*, "An adenovirus vector for gene transfer into neurons and glia in the brain," *Science*, 259:988-990, 1993.
- 20 Levrero *et al.*, "Defective and nondefective adenovirus vectors for expressing foreign genes *in vitro* and *in vivo*," *Gene*, 101: 195-202, 1991.
- Li *et al.*, "Assessment of recombinant adenoviral vectors for hepatic gene therapy,"
25 *Hum. Gene Ther.*, 4:403-409, 1993.
- Linzer and Levine, "Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells,"
Cell, 17:43-52, 1979.

- Lowe *et al.*, "*p53* is required for radiation-induced apoptosis in mouse thymocytes," *Nature*, 362:847-849, 1993.
- 5
- Maestro *et al.*, "High frequency of *p53* gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx," *Oncogene*, 7:1159-1166, 1992.
- 10
- Mann *et al.*, "Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus," *Cell*, 33:153-159, 1983.
- Markowitz *et al.*, "A safe packaging line for gene transfer: Separating viral genes on two different plasmids," *J. Virol.*, 62:1120-1124, 1988.
- 15
- Martinez *et al.*, "Cellular localization and cell cycle regulation by a temperature-sensitive *p53* protein," *Genes Dev.*, 5:151-159, 1991.
- Marx, "Learning how to suppress cancer," *Science*, 261:1385-1387, 1993.
- 20
- Mashal *et al.*, "Rearrangement and expression of *p53* in the chronic phase and blast crisis of chronic myelogenous leukemia," *Blood*, 75:180-189, 1990.
- Matlashewski *et al.*, "Isolation and characterization of a human *p53* cDNA clone: expression of the human *p53* gene," *The EMBO Journal*, 3(13):3257-3262,
- 25
- 1984.

- 102 -

Mercer *et al.*, "Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type *p53*," *Proc. Natl. Acad. Sci. USA*, 87:6166-6170, 1990.

- 5 Merino *et al.*, "An Analysis of Distant Metastasis From Squamous Cell Carcinoma of the Upper Respiratory and Digestive Tracts," *Cancer*, 40:147-156, 1977.

Mietz *et al.*, "The transcriptional transactivation function of wild-type *p53* is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein," *EMBO J.*,
10 11:5013-5020, 1992.

Mitsudomi *et al.*, "*p53* gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of *ras* mutations and clinical features," *Oncogene*, 7:171-180, 1992.

15

Mukhopadhyay *et al.*, "Specific Inhibition of K-*ras* Expression and Tumorigenicity of Lung Cancer Cells by Antisense RNA," *Cancer Res.*, 51:1744-1748, 1991.

20

Mulcahy *et al.*, "Requirements for *ras* protoonogene function during serum-stimulated growth of NIH/3T3 cells," *Nature*, 313:241-243, 1985.

Mulligan, "The Basic Science of Gene Therapy," *Science*, 260:926-932, 1993.

Myers, EPO 0273085

25

Nicolau *et al.*, "Liposomes as carriers for *in vivo* gene transfer and expression," *Methods Enzymol.*, 149:157-176, 1987.

- 103 -

- Nicolau and Sene, "Liposome-mediated DNA transfer in eukaryotic cells," *Biochem. Biophys. Acta*, 721:185-190, 1982.
- 5 Nylander *et al.*, "*p53* Expression and Cell Proliferation in Squamous Cell Carcinomas of the Head and Neck," *Cancer*, 75:87-93, 1995.
- O'Malley, Jr. *et al.*, "Adenovirus-mediated Gene Therapy for Human Head and Neck Squamous Cell Cancer in a Nude Mouse Model," *Cancer Res*, 55:1080-1085, 1995.
- 10 Ogiso *et al.*, "Suppression of various human tumor cell lines by a dominant negative H-*ras* mutant," *Gene Ther.*, 1:403-407, 1994.
- Oren and Levine, "Molecular cloning of a cDNA specific for the murine *p53* cellular tumor antigen," *Proc. Natl. Acad. Sci. USA*, 80:56-59, January 1983.
- 15 Pavelic *et al.*, "Overexpression of *p53* Protein is Common in Premalignant Head and Neck Lesions," *Anticancer Research*, 14:2259-2266, 1994.
- 20 Perales *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:4086-4090, 1994.
- Potter *et al.*, "Enhancer-dependent expression of human k immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation," *Proc. Nat'l Acad. Sci. USA*, 81:7161-7165, 1984.
- 25 Racher *et al.*, *Biotechnology Techniques*, 9:169-174, 1995.
- Ragot *et al.*, "Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice," *Nature*, 361:647-650, 1993.

- Ramqvist *et al.*, "Wild-type *p53* induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant *p53*," *Oncogene*, 8:1495-1500, 1993.
- 5 Rao *et al.*, "The adenovirus E1A proteins induce apoptosis which is inhibited by the E1B 19K and Bcl-2 proteins," *Proc. Natl. Acad. Sci. USA*, 89:7742-7746, 1992.
- 10 Renan, "Cancer genes: current status, future prospects, and applicants in radiotherapy/oncology," *Radiother. Oncol.*, 19:197-218, 1990.
- Rich *et al.*, "Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis," *Hum. Gene Ther.*, 4:461-476, 1993.
- 15 Ridgeway, "Mammalian expression vectors," *In*: Rodriguez RL, Denhardt DT, ed. Vectors: A survey of molecular cloning vectors and their uses. Stoneham: Butterworth, pp. 467-492, 1988.
- 20 Rippe *et al.*, "DNA-mediated gene transfer into adult rat hepatocytes in primary culture," *Mol. Cell Biol.*, 10:689-695, 1990.
- Rodrigues *et al.*, "*p53* mutations in colorectal cancer," *Proc. Natl. Acad. Sci. USA*, 87:7555-7559, 1990.
- 25 Rosenfeld *et al.*, "*in vivo* transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium," *Cell*, 68:143-155, 1992.
- Rosenfeld *et al.*, "Adenovirus-mediated transfer of a recombinant α 1-antitrypsin gene to the lung epithelium *in vivo*," *Science*, 252:431-434, 1991.

Roth *et al.*, U.S. Serial No. 07/987,235

5 Sacks *et al.*, "Establishment and Characterization of Two New Squamous Cell
Carcinoma Cell Lines Derived from Tumors of the Head and Neck," *Cancer*
Res., 48:2858-2866, 1988.

10 Shaulsky *et al.*, "Nuclear accumulation of *p53* protein is mediated by several nuclear
localization signals and plays a role in tumorigenesis," *Mol Cell Biol*,
10(12):6565-6567, 1990.

Shaw *et al.*, "Induction of apoptosis by wild-type *p53* in a human colon tumor-derived
cell line," *Proc. Natl. Acad. Sci. USA*, 89:4495-4499, 1992.

15 Shirasawa *et al.*, "Altered Growth of Human Colon Cancer Cell Lines Disrupted at
Activated Ki-ras," *Science*, 260:85-88, 1993.

20 Somers *et al.*, "Amplification of the int-2 gene in human head and neck squamous cell
carcinomas," *Oncogene*, 5:915-920, 1990.

Southern and Berg, "Transformation of Mammalian Cells to Antibiotic Resistance
with a Bacterial Gene Under Control of the SV40 Early Region Promoter," *J.*
Mol. App. Gen., 1:327-341, 1982.

25 Stratford-Perricaudet and Perricaudet, "Gene transfer into animals: the promise of
adenovirus," p. 51-61, *In: Human Gene Transfer*, Eds, O. Cohen-Haguenaer
and M. Boiron, Editions John Libbey Eurotext, France, 1991.

- 106 -

- Stratford-Perricaudet *et al.*, "Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector," *Hum. Gene Ther.*, 1:241-256, 1990.
- 5 Su *et al.*, "Production of Recombinant Porcine Tumor Necrosis Factor Alpha in a Novel E.coli Expression System," *Biotechniques*, 13(5):756-761, 1992.
- Tabin *et al.*, *Nature*, 300:143-149, 1982.
- 10 Takahashi *et al.*, "The *p53* gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern," *Cancer Res.*, 52:734-736, 1992.
- Thawley and Panje, eds, "Comprehensive Management of Head and Neck Tumors,"
15 Philadelphia: WB Saunders, 2:1158-1172, 1987.
- Top *et al.*, "Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7," *J. Infect. Dis.*, 124:155-160, 1971.
- 20 Tur-Kaspa *et al.*, "Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes," *Mol. Cell Biol.*, 6:716-718, 1986.
- van der Riet *et al.*, "Frequent loss of chromosome 9 p21-22 early in head and neck
25 cancer progression," *Cancer Res.*, 54:1156-1158, 1994.
- Wagner *et al.*, *Science*, 260:1510-1513, 1993.

- 107 -

Wang *et al.*, "Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytotoxic effect of AdCMV-*p53*," *Cancer Gene Therapy*, 2(1):1-9, 1995.

- 5 Watling *et al.*, "Overexpression of *p53* in Head and Neck Cancer," *Head and Neck*, 14:437-444, 1992.

Wijnsman *et al.*, "A new method to detect apoptosis in paraffin section: *in situ* end-labeling of fragmented DNA," *J. Histochem. Cytochem.*, 41:7-12, 1993.

10

Wilcock and Lane, "Localization of *p53*, retinoblastoma, and host replication proteins at sites of viral replication in herpes-infected cells," *Nature*, 349:429-431, 1991.

- 15 Wong *et al.*, "Appearance of β -lactamase activity in animal cells upon liposome mediated gene transfer," *Gene*, 10:87-94, 1980.

Wu and Wu, "Receptor-mediated *in vitro* gene transfections by a soluble DNA carrier system," *J. Biol. Chem.*, 262:4429-4432, 1987.

20

Wu and Wu, *Adv. Drug Delivery Rev.*, 12:159-167, 1993.

Wu and Wu, "Evidence for targeted gene delivery to HepG2 hepatoma cells *in vitro*," *Biochemistry*, 27:887-892, 1988.

25

Wu and Levine, "*p53* and E2F-1 cooperate to mediate apoptosis," *Proc. Natl. Acad. Sci. USA*, 91:3602-3606, 1994.

- 108 -

- Yamamoto *et al.*, "High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines," *Cancer Res.*, 46:414-416, 1986.
- 5 Yang *et al.*, "*in vivo* and *in vitro* gene transfer to mammalian somatic cells by particle bombardment," *Proc. Nat'l Acad. Sci. USA*, 87:9568-9572, 1990.
- Yonish-Rouach *et al.*, "Wild-type *p53* induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6," *Nature*, 352:345-347, 1991.
- 10 Yuasa *et al.*, *Nature*, 303:775-559, 1983.
- Zelenin *et al.*, "High-velocity mechanical DNA transfer of the chloramphenicol acetyltransferase gene into rodent liver, kidney and mammary gland cells in
- 15 organ explants and *in vivo*," *FEBS Lett.*, 280:94-96, 1991.
- Zhang *et al.*, U.S. Serial No. 08/423,573
- Zhang and Roth, U.S. Serial No. 08/222,285
- 20 Zhang *et al.*, "Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis," *Biotechniques*, 15:868-872, 1993.
- 25 Zhang *et al.*, "High-efficiency gene transfer and high-level expression of wild-type *p53* in human lung cancer cells mediated by recombinant adenovirus," *Cancer Gene Therapy*, 1:1-10, 1994.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: BOARD OF REGENTS, THE UNIVERSITY
OF TEXAS SYSTEM
- (B) STREET: 201 WEST 7TH STREET
- (C) CITY: AUSTIN
- (D) STATE: TEXAS
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 78701

(ii) TITLE OF INVENTION: METHODS AND COMPOSITIONS
FOR THE DIAGNOSIS OF CANCER

(iii) NUMBER OF SEQUENCES: 14

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version
#1.30 (EPO)

(v) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: UNKNOWN
- (B) FILING DATE: CONCURRENTLY HEREWITH
- (C) CLASSIFICATION: UNKNOWN

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 60/007,810
- (B) FILING DATE: 30-NOV-1995

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2066 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

	CAAAACCTAC CAGGGCAGCT ACGGTTTCCG TCTGGGCTTC TTGCATTCTG GGACAGCCAA	60
5	GTCTGTGACT TGCACGTACT CCCCTGCCCT CAACAAGATG TTTTGCCAAC TGGCCAAGAC	120
	CTGCCCTGTG CAGCTGTGGG TTGATTCCAC ACCCCCGCCC GGCACCCGCG TCCGCGCCAT	180
	GGCCATCTAC AAGCAGTCAC AGCACATGAC GGAGGTTGTG AGGCGCTGCC CCCACCATGA	240
10	GCGCTGCTCA GATAGCGATG GTCTGGCCCC TCCTCAGCAT CTTATCCGAG TGGAAGGAAA	300
	TTTGCGTGTG GAGTATTTGG ATGACAGAAA CACTTTTCGA CATAGTGTGG TGGTGCCCTA	360
15	TGAGCCGCCT GAGGTTGGCT CTGACTGTAC CACCATCCAC TACAAC TACA TGTGTAACAG	420
	TTCCTGCATG GCGGGCATGA ACCGGAGGCC CATCCTCACC ATCATCACAC TGGAAGACTC	480
	CAGTGGTAAT CTA CTACTGGGAC GGAACAGCTT TGAGGTGCGT GTTTGTGCCT GTCCTGGGAG	540
20	AGACCGGCGC ACAGAGGAAG AGAATCTCCG CAAGAAAGGG GAGCCTCACC ACGAGCTGCC	600
	CCCAGGGAGC ACTAAGCGAG CACTGCCCAA CAACACCAGC TCCTCTCCCC AGCCAAAGAA	660
25	GAAACCACTG GATGGAGAAT ATTTACCCCT TCAGATCCGT GGGCGTGAGC GCTTCGAGAT	720
	GTTCCGAGAG CTGAATGAGG CTTTGGA ACT CAAGGATGCC CAGGCTGGGA AGGAGCCAGG	780

	GGGGAGCAGG GCTCACTCCA GCCACCTGAA GTCCAAAAAG GGTCAGTCTA CCTCCCGCCA	840
	TAAAAAACTC ATGTTCAAGA CAGAAGGGCC TGA CTCAGAC TGACATTCTC CACTTCTTGT	900
5	TCCCCACTGA CAGCCTCCCA CCCCCATCTC TCCCTCCCCT GCGATTTTGG GTTTTGGGTC	960
	TTTGAACCCT TGCTTGCAAT AGGTGTGCGT CAGAAGCACC CAGGACTTCC ATTTGCTTTG	1020
	TCCCGGGGCT CCACTGAACA AGTTGGCCTG CACTGGTGTT TTGTTGTGGG GAGGAGGATG	1080
10	GGGAGTAGGA CATA CCAGCT TAGATTTTAA GGT TTTTACT GTGAGGGATG TTTGGGAGAT	1140
	GTAAGAAATG TTCTTGCAGT TAAGGGTTAG TTTACAATCA GCCACATTCT AGGTAGGGGC	1200
15	CCACTTCACC GTACTAACCA GGGAAGCTGT CCCTCACTGT TGAATTTTCT CTA ACTTCAA	1260
	GGCCCATATC TGTGAAATGC TGGCATTTCG ACCTACCTCA CAGAGTGCAT TGTGAGGGTT	1320
	AATGAAATAA TGTACATCTG GCCTTGAAAC CACCTTTTAT TACATGGGGT CTAGAACTTG	1380
20	ACCCCTTGA GGGTGCTTGT TCCCTCTCCC TGTTGGTCGG TGGGTGGTA GTTTCTACAG	1440
	TTGGGCAGCT GGTTAGGTAG AGGGAGTTGT CAAGTCTCTG CTGGCCCAGC CAAACCCTGT	1500
25	CTGACAACCT CTTGGTGAAC CTTAGATCCT AAAAGGAAAT GTCACCCCAT CCCACACCCT	1560
	GGAGGATTTT ATCTCTTGTA TAGATGATCT GGATCCACCA AGACTTGTTT TAGCTCAGGG	1620

5 TCCAATTTCT TTTTCTTTT TTTTTTTTTT TTTCTTTTC TTTGAGACTG GGTCTCTTTG 1680
TTGCCCCAGG CTGGAGTGGA GTGGCGTGAT CTGGCTTACT GCAGCCTTTG CCTCCCCGGC 1740
10 TCGAGCAGTC CTGCCTCAGC CTCCGGAGTA GCTGGGACCA CAGGTTTCATG CCACCATGGC 1800
CAGCCAACTT TTGCATGTTT TGTAGAGATG GGGTCTCACA GTGTTGCCCA GGCTGGTCTC 1860
AAACTCCTGG GCTCAGGCGA TCCACCTGTC TCAGCCTCCC AGAGTGCTGG GATTACAATT 1920
15 GTGAGCCACC ACGTCCAGCT GGAAGGGTCA ACATCTTTTA CATTCTGCAA GCACATCTGC 1980
ATTTTCACCC CACCCTTCCC CTCTTCTCCC TTTTATATC CCATTTTAT ATCGATCTCT 2040
TATTTTACAA TAAAACTTTG CTGCCA 2066

-112-

(2) INFORMATION FOR SEQ ID NO: 2:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 293 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
25 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

5	Lys	Thr	Tyr	Gln	Gly	Ser	Tyr	Gly	Phe	Arg	Leu	Gly	Phe	Leu	His	Ser	
	1				5					10					15		
	Gly	Thr	Ala	Lys	Ser	Val	Thr	Cys	Thr	Tyr	Ser	Pro	Ala	Leu	Asn	Lys	
				20					25					30			
10	Met	Phe	Cys	Gln	Leu	Ala	Lys	Thr	Cys	Pro	Val	Gln	Leu	Trp	Val	Asp	
			35					40					45				
	Ser	Thr	Pro	Pro	Pro	Gly	Thr	Arg	Val	Arg	Ala	Met	Ala	Ile	Tyr	Lys	
		50					55					60					
15	Gln	Ser	Gln	His	Met	Thr	Glu	Val	Val	Arg	Arg	Cys	Pro	His	His	Glu	
	65					70					75					80	
	Arg	Cys	Ser	Asp	Ser	Asp	Gly	Leu	Ala	Pro	Pro	Gln	His	Leu	Ile	Arg	
					85					90					95		
20	Val	Glu	Gly	Asn	Leu	Arg	Val	Glu	Tyr	Leu	Asp	Asp	Arg	Asn	Thr	Phe	
				100					105					110			
	Arg	His	Ser	Val	Val	Val	Pro	Tyr	Glu	Pro	Pro	Glu	Val	Gly	Ser	Asp	
25			115					120					125				
	Cys	Thr	Thr	Ile	His	Tyr	Asn	Tyr	Met	Cys	Asn	Ser	Ser	Cys	Met	Gly	
	130						135					140					

	Gly	Met	Asn	Arg	Arg	Pro	Ile	Leu	Thr	Ile	Ile	Thr	Leu	Glu	Asp	Ser	
	145					150					155					160	
5	Ser	Gly	Asn	Leu	Leu	Gly	Arg	Asn	Ser	Phe	Glu	Val	Arg	Val	Cys	Ala	
					165					170					175		
	Cys	Pro	Gly	Arg	Asp	Arg	Arg	Thr	Glu	Glu	Glu	Asn	Leu	Arg	Lys	Lys	
				180					185					190			
10	Gly	Glu	Pro	His	His	Glu	Leu	Pro	Pro	Gly	Ser	Thr	Lys	Arg	Ala	Leu	
			195					200					205				
	Pro	Asn	Asn	Thr	Ser	Ser	Ser	Pro	Gln	Pro	Lys	Lys	Lys	Pro	Leu	Asp	
15		210					215					220					
	Gly	Glu	Tyr	Phe	Thr	Leu	Gln	Ile	Arg	Gly	Arg	Glu	Arg	Phe	Glu	Met	
	225					230				235						240	
20	Phe	Arg	Glu	Leu	Asn	Glu	Ala	Leu	Glu	Leu	Lys	Asp	Ala	Gln	Ala	Gly	
					245					250					255		
	Lys	Glu	Pro	Gly	Gly	Ser	Arg	Ala	His	Ser	Ser	His	Leu	Lys	Ser	Lys	
				260					265					270			
25	Lys	Gly	Gln	Ser	Thr	Ser	Arg	His	Lys	Lys	Leu	Met	Phe	Lys	Thr	Glu	
			275					280					285				

Gly Pro Asp Ser Asp
290

5 (2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 2066 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

15 CAAAACTTAC CAGGGCAACT ATGGCTTCCA CCTGGGCTTC CTGCAGTCTG GGACAGCCAA 60
GTCTGTTATG TGCACGTACT CTCCTCCCCT CAATAAGCTA TTCTGCCAGC TGGCGAAGAC 120
GTGCCCTGTG CAGTTGTGGG TCAGCGCCAC ACCTCCAGCT GGGAGCCGTG TCCGCGCCAT 180
20 GGCCATCCAC AAGAAGTCAC AGCACTTGAC GGGGGTCGTG AGACGCTGCC CCCACCATGA 240
GCGCTGCTCC GATGGTGATG GCCTGGCTCC TCCCAGCAT CTTATCCGGG TGGAAGGAAA 300
25 TTTGTATCCC GAGTATCTGG AAGACAGGCA GACTTTTCGC CACAGCGTGG TGGTACCTTA 360
TGAGCCACCC GAGGCCGGCT CTGAGTATAC CACCATCCAC TACAAGTACA TTTGTAATAG 420

	CTCCTGCATG GGGGGCATGA ACCGCCGACC TATCCTTACC ATCATCACAC TGGAAGACTC	480
	CAGTGGGAAC CTTCTGGGAC GGGACAGCTT TGAGGTTCGT GTTTGTGCCT GCCCTGGGAG	540
5	AGACCGCCGT ACAGAAGAAG AAAATTTCCG CAAAAAGGAA GTCCTTTGCC CTGAACTGCC	600
	CCCAGGGAGC GCAAAGAGAG CGCTGCCCAC CTGCACAAGC GCCTCTCCCC CGCAAAAGAA	660
	AAAACCACTT GATGGAGAGT ATTTACCCCT CAAGATCCGC GGGCGTAAAC GCTTCGAGAT	720
10	GTTCCGGGAG CTGAATGAGG CCTTAGAGTT AAAGGATGCC CATGCTACAG AGGAGTCTGG	780
	AGACAGCAGG GCTCACTCCA GCTACCTGAA GACCAAGAAG GGCCAGTCTA CTTCCCGCCA	840
15	TAAAAAACA ATGGTCAAGA AAGTGGGGCC TGA CTCAGAC TGACATTCTC CACTTCTTGT	900
	TCCCCACTGA CAGCCTCCCA CCCCCATCTC TCCCTCCCCT GCCTTTTGGG TTTTGGGTCT	960
	TTGAACCCTT GCTTGCAATA GGTGTGCGTC AGAAGCACCC AGGACTTCCA TTTGCTTTGT	1020
20	CCCGGGGCTC CACTGAACAA GTTGGCCTGC ACTGGTGTTT TGTTGTGGGG AGGAGGATGG	1080
	GGAGTAGGAC ATACCAGCTT AGATTTTAAG GTTTTTACTG TGAGGGATGT TTGGGAGATG	1140
25	TAAGAAATGT TCTTGCAGTT AAGGGTTAGT TTACAATCAG CCACATTCTA GGTAGGGGCC	1200
	CACTTCACCG TACTAACCAG GGAAGCTGTC CCTCACTGTT GAATTTTCTC TAACTTCAAG	1260

	GCCCATATCT GTGAAATGCT GGCATTTGCA CCTACCTCAC AGAGTGCATT GTGAGGGTTA	1320
	ATGAAATAAT GTACATCTGG CCTTGAAACC ACCTTTTATT ACATGGGGTC TAGATGACCC	1380
5	CCTTGAGGTG CTTGTTCCCT CTCCCTGTTG GTCGGTGGGT TGGTAGTTTC TACAGTTGGG	1440
	CAGCTGGTTA GGTTGAGGTA GTTGTCAGGT CTCTGCTGGC CCAGCGAAAT TCTATCCAGC	1500
	CAGTTGTTGG ACCCTGGCAC CTCAAATGAA ATCTCACCTT ACCCCACACC CTGTAAGATT	1560
10	CTATCTCTTG TATAGATGAT CTGGATCCAC CAAGACTTGT TTTAGCTCAG GGTCCAATTT	1620
	CTTTTTTCTT TTTTTTTTTT TTTTCTTTT TCTTTGAGAC TGGGTCTCTT TGTTGCCCCA	1680
15	GGCTGGAGTG GAGTGGCGTG ATCTGGCTTA CTGCAGCCTT TGCCTCCCCG GCTCGAGCAG	1740
	TCCTGCCTCA GCCTCCGGAG TAGCTGGGAC CACAGGTTCA TGCCACCATG GCCAGCCAAC	1800
	TTTTGCATGT TTTGTAGAGA TGGGGTCTCA CAGTGTTGCC CAGGCTGGTC TCAAACCTCT	1860
20	GGGCTCAGGC GATCCACCTG TCTCAGCCTC CCAGAGTGCT GGGATTACAA TTGTGAGCCA	1920
	CCACGTCCAG CTGGAAGGGC CTACTTTCCT TCCATTCTGC AAAGCCCTGC TGCATTTATC	1980
25	CACCCACCC TCCACCTGTC TCCCTCTTTT TTTCTTACCC CTTTTTATAT ATCAATTTCT	2040
	TATTTTACAA TAAAATTTTG TTATCA	2066

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

5

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Lys Thr Tyr Gln Gly Asn Tyr Gly Phe His Leu Gly Phe Leu Gln Ser
 1 5 10 15

15

Gly Thr Ala Lys Ser Val Met Cys Thr Tyr Ser Pro Pro Leu Asn Lys
 20 25 30

20

Leu Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln Leu Trp Val Ser
 35 40 45

Ala Thr Pro Pro Ala Gly Ser Arg Val Arg Ala Met Ala Ile His Lys
 50 55 60

25

Lys Ser Gln His Met Thr Gly Val Val Arg Arg Cys Pro His His Glu
 65 70 75 80

	Arg	Cys	Ser	Asp	Gly	Asp	Gly	Leu	Ala	Pro	Pro	Gln	His	Leu	Ile	Arg	
				85						90					95		
5	Val	Glu	Gly	Asn	Leu	Tyr	Pro	Glu	Tyr	Leu	Glu	Asp	Arg	Gln	Thr	Phe	
				100					105					110			
	Arg	His	Ser	Val	Val	Val	Pro	Tyr	Glu	Pro	Pro	Glu	Ala	Gly	Ser	Glu	
			115					120					125				
10	Tyr	Thr	Thr	Ile	His	Tyr	Lys	Tyr	Ile	Cys	Asn	Ser	Ser	Cys	Met	Gly	
		130					135					140					
	Gly	Met	Asn	Arg	Arg	Pro	Ile	Leu	Thr	Ile	Ile	Thr	Leu	Glu	Asp	Ser	
15		145				150					155					160	
	Ser	Gly	Asn	Leu	Leu	Gly	Arg	Asn	Ser	Phe	Glu	Val	Arg	Val	Cys	Ala	
				165						170					175		
	Cys	Pro	Gly	Arg	Asp	Arg	Arg	Thr	Glu	Glu	Glu	Asn	Phe	Arg	Lys	Lys	
20				180					185					190			
	Glu	Val	Leu	Cys	Pro	Glu	Leu	Pro	Pro	Gly	Ser	Ala	Lys	Arg	Ala	Leu	
			195					200					205				
25	Pro	Thr	Cys	Thr	Ser	Ala	Ser	Pro	Pro	Gln	Lys	Lys	Lys	Pro	Leu	Asp	
		210					215					220					

5 Gly Glu Tyr Phe Thr Leu Lys Ile Arg Gly Arg Leu Arg Phe Glu Met
225 230 235 240

Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala His Ala Thr
245 250 255

Glu Glu Ser Gly Asp Ser Arg Ala His Ser Ser Tyr Leu Lys Ser Lys
260 265 270

10 Lys Gly Gln Ser Thr Ser Arg His Lys Lys Thr Met Val Lys Lys Val
275 280 285

Gly Pro Asp Ser Asp
290

15

(2) INFORMATION FOR SEQ ID NO: 5:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ACTGCCCAAC AACACCA

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCCACGCCCA CACATTT

17

15 (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

25 GCCTGTCCTG GGAGAGACCG

20

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CCCTTAAGCC ACGCCCACAC

20

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CACTGCCCAA CAACACCA

18

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GCCACGCCCA CACATT

17

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GGTGCATTGG AACGCGGATT

20

5

10

15

20

25

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GGGGACAGAA CGTTGTTTTC

20

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

ACGGATTTGG TCGTATTGGG

20

5

10

15

20

25

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

10

TGATTTTGGA GGGATCTCGC

20

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A viral expression construct when used in a method of inhibiting growth of a p53-positive tumor cell in a mammalian subject with a solid tumor, wherein said expression construct comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional p53 polypeptide, wherein said polynucleotide is positioned sense to and under the control of said promoter and wherein said method comprises the steps of:

(a) providing the viral expression construct; and

(b) directly administering said viral expression construct to said tumor *in vivo*, the administration resulting in expression of said functional p53 polypeptide in cells of said tumor and inhibition of tumor cell growth,



wherein said tumor comprises cells that express a functional p53 polypeptide.

2. The viral expression construct of Claim 1, wherein said tumor is selected from the group consisting of a carcinoma, a glioma, a sarcoma, and a melanoma.

3. The viral expression construct of Claim 1, wherein said tumor cell is malignant.

4. The viral expression construct of Claim 1, wherein said tumor cell is benign.

5. The viral expression construct of Claim 1, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.



6. The viral expression construct of Claim 1, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.
7. The viral expression construct of Claim 6, wherein said viral vector is a replication-deficient adenoviral vector.
8. The viral expression construct of Claim 7, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.
9. The viral expression construct of Claim 8, wherein said promoter is a CMV IE promoter.
10. The viral expression construct of Claim 1, wherein said subject is a human.
11. The viral expression construct of Claim 7, wherein the expression vector is administered to said tumor at least a second time.
12. The viral expression construct of Claim 11, wherein said tumor is resected following at least a second administration, and an additional administration is effected subsequent to said resection.
13. The viral expression construct of Claim 1, wherein said expression vector is administered in a volume of about 3 ml. to about 10 ml.
14. The viral expression construct of Claim 11, wherein the amount of adenovirus administered in each contacting is between about 10^7 and 10^{12} pfu.



15. The viral expression construct of Claim 1, wherein the expression construct is injected into a natural or artificial body cavity.
16. The viral expression construct of Claim 15, wherein said injection comprises continuous perfusion of said natural or artificial body cavity.
17. The viral expression construct of Claim 15, wherein said contacting is via injection into an artificial body cavity resulting from tumor excision.
18. The viral expression construct of Claim 1, wherein the *p53*-encoding polynucleotide is tagged so that expression of *p53* from said expression vector can be detected.
19. The viral expression construct of Claim 18, wherein the tag is a continuous epitope.
20. The viral expression construct of Claim 1, wherein said tumor is contacted with said expression construct at least twice.
21. The viral expression construct of Claim 20, wherein said multiple injections comprise about 0.1 - 0.5 ml volumes spaced about 1 cm apart.
22. The viral expression construct of Claim 1, wherein the method further comprises contacting said tumor with a DNA damaging agent.
23. The viral expression construct of Claim 22, wherein said DNA damaging agent is a radiotherapeutic agent.



24. The viral expression construct of Claim 23, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.

25. The viral expression construct of Claim 22, wherein said DNA damaging agent is a chemotherapeutic agent.

26. The viral expression construct of Claim 25, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.

27. The viral expression construct of Claim 1, wherein the method further comprises contacting said tumor with a cytokine.

28. The viral expression construct of Claim 1, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a *p53* polypeptide.

29. The viral expression construct of Claim 28, wherein said second therapeutic gene is selected from the group consisting of a *Dp* gene, *p21*, *p16*, *p27*, *E2F*, *Rb*, *APC*, *DC*, *NF-1*, *NF-2*, *WT-1*, *MEN-I*, *MEN-II*, *BRCA1*, *VHL*, *FCC*, *MCC*, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, *Bax*, *Bcl-X_s* and *E1A*.

30. The viral expression construct of Claim 1, wherein said tumor is located into a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.



31. The viral expression construct of Claim 11, wherein said tumor is contacted with said expression construct at least six times within a two week treatment regimen.

32. A viral expression construct when used in a method for inhibiting microscopic residual tumor cell growth in a mammalian subject, wherein said expression construct comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional p53 polypeptide, wherein said polynucleotide is positioned sense to and under the control of said promoter, and wherein said method comprises the steps of:

- (a) identifying a mammalian subject having a resectable tumor;
- (b) resecting said tumor; and
- (c) administering to a tumor bed revealed by resection the viral expression construct, the administration resulting in expression of said functional p53 polypeptide in said tumor cells and inhibition of their growth.

33. The viral expression construct of Claim 32, wherein said resectable tumor is a squamous cell carcinoma.

34. The viral expression construct of Claim 32, wherein the endogenous *p53* of said resectable tumor is mutated.

35. The viral expression construct of Claim 32, wherein the endogenous *p53* of said resectable tumor is wild-type.



36. The viral expression construct of Claim 32, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.

37. The viral expression construct of Claim 32, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.

38. The viral expression construct of Claim 37, wherein said adenoviral vector is a replication-deficient adenoviral vector.

39. The viral expression construct of Claim 38, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.

40. The viral expression construct of Claim 32, wherein said promoter is a CMV IE promoter.

41. The viral expression construct of Claim 32, wherein the resulting tumor bed is contacted with said expression construct at least twice.

42. The viral expression construct of Claim 32, wherein said expression construct is contacted with said tumor bed prior to closing of the incision.

43. The viral expression construct of Claim 38, wherein said tumor bed is contacted with from about 10^6 to about 10^9 infectious adenoviral particles.

44. The viral expression construct of Claim 41, wherein the method further comprises contacting said tumor with said expression construct prior to resecting said tumor.



45. The viral expression construct of Claim 44, wherein said tumor is injected with said expression construct.

46. The viral expression construct of Claim 45, wherein said tumor is injected with about 10^6 to about 10^9 infectious adenoviral particles.

47. The viral expression construct of Claim 45, wherein said tumor is injected with a total of about 1 ml to about 10 ml.

48. The viral expression construct of Claim 45, wherein said tumor is injected at least twice.


49. The viral expression construct of Claim 48, wherein each of said injections comprise about 0.1 ml to about 0.5 ml volumes spaced about 1 cm apart.

50. The viral expression construct of Claim 32, wherein the resulting tumor bed is contacted with said expression construct through a catheter.

51. The viral expression construct of Claim 48, wherein said contacting comprises about 10^6 to about 10^9 infectious adenoviral particles.

52. The viral expression construct of Claim 48, wherein said expression construct is contacted with said tumor in total of about 3 ml to about 10 ml.

53. The viral expression construct of Claim 32, wherein the *p53* polynucleotide is tagged so that expression of a *p53* polypeptide can be detected.



54. The viral expression construct of Claim 53, wherein the tag is a continuous epitope.

55. The viral expression construct of Claim 32, wherein the method further comprises contacting said tumor with a DNA damaging agent.

56. The viral expression construct of Claim 55, wherein said DNA damaging agent is contacted before resection.

57. The viral expression construct of Claim 55, wherein said DNA damaging agent is contacted after resection.

58. The viral expression construct of Claim 55, wherein said DNA damaging agent is contacted before and after resection.

59. The viral expression construct of Claim 55, wherein said DNA damaging agent is a radiotherapeutic agent.

60. The viral expression construct of Claim 59, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.

61. The viral expression construct of Claim 55, wherein said DNA damaging agent is a chemotherapeutic agent.

62. The viral expression construct of Claim 61, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-



fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.

63. The viral expression construct of Claim 32, wherein the method further comprises contacting said tumor with a cytokine.

64. The viral expression construct of Claim 63, wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TGF- β , GM-CSF, M-CSF, TNF α , TNF β , LAF, TCGF, BCGF, TRF, BAF, BDG, MP, LIF, OSM, TMF, PDGF, IFN- α , IFN- β and IFN- γ .

65. The viral expression construct of Claim 32, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a *p53* polypeptide.

66. The viral expression construct of Claim 65, wherein said second therapeutic gene is selected from the group consisting of a Dp gene, p21, p16, p27, E₂F, Rb, APC, DC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, FCC, MCC, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, Bax, Bcl-X_s and E1A.

67. The viral expression construct of Claim 32, wherein said tumor is located into a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.

68. A viral expression construct when used in a method for inhibiting growth of a tumor cell in a mammalian subject having a solid tumor, wherein said expression construct



comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional p53 polypeptide, wherein said polynucleotide is positioned sense to and under the control of said promoter and wherein said method comprises the steps of:

- (a) surgically revealing said tumor; and
- (b) directly administering to said tumor the viral expression construct, the administration resulting in expression of said functional p53 polypeptide in said tumor cells and inhibition of their growth.

69. The viral expression construct of Claim 68, wherein said tumor is malignant.

70. The viral expression construct of Claim 68, wherein said tumor is a squamous cell carcinoma.

71. The viral expression construct of Claim 68, wherein said tumor is benign.

72. The viral expression construct of Claim 68, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.

73. The viral expression construct of Claim 68, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.

74. The viral expression construct of Claim 73, wherein said adenoviral vector is a replication-deficient adenoviral vector.



75. The viral expression construct of Claim 74, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.

76. The viral expression construct of Claim 68, wherein said promoter is a CMV IE promoter.

77. The viral expression construct of Claim 68, wherein said tumor is contacted with said expression construct at least twice.

78. The viral expression construct of Claim 68, wherein said expression construct is contacted with said tumor prior to closing of the incision.


79. The viral expression construct of Claim 74, wherein said tumor is contacted with from about 10^6 to about 10^9 infectious adenoviral particles.

80. The viral expression construct of Claim 68, wherein said tumor is contacted with said expression construct in a total of about 1 ml to about 10 ml.

81. The viral expression construct of Claim 68, wherein said tumor is injected at least twice.

82. The viral expression construct of Claim 81, wherein each of said injections comprise about 0.1 ml to about 0.5 ml volumes spaced about 1 cm apart.

83. The viral expression construct of Claim 68, wherein said tumor is contacted with said expression construct through a catheter.



84. The viral expression construct of Claim 83, wherein said tumor is contacted with about 10^6 to about 10^9 infectious adenoviral particles.

85. The viral expression construct of Claim 83, wherein said tumor is contacted with an expression construct in a total of about 3 ml to about 10 ml.

86. The viral expression construct of Claim 68, wherein the *p53* polynucleotide is tagged so that expression of a *p53* polypeptide can be detected.

87. The viral expression construct of Claim 86, wherein the tag is a continuous epitope.

88. The viral expression construct of Claim 68, wherein the method further comprises contacting said tumor with a DNA damaging agent.

89. The viral expression construct of Claim 88, wherein said DNA damaging agent is contacted with said tumor before resection.

90. The viral expression construct of Claim 88, wherein said DNA damaging agent is contacted with said tumor after resection.

91. The viral expression construct of Claim 88, wherein DNA damaging agent is contacted with said tumor before and after resection.

92. The viral expression construct of Claim 88, wherein said DNA damaging agent is a radiotherapeutic agent.



93. The viral expression construct of Claim 92, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.

94. The viral expression construct of Claim 88, wherein said DNA damaging agent is a chemotherapeutic agent.

95. The viral expression construct of Claim 94, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.

96. The viral expression construct of Claim 68, wherein the method further comprises contacting said tumor with a cytokine.

97. The viral expression construct of Claim 96, wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TGF- β , GM-CSF, M-CSF, TNF α , TNF β , LAF, TCGF, BCGF, TRF, BAF, BDG, MP, LIF, OSM, TMF, PDGF, IFN- α , IFN- β , and IFN- γ .

98. The viral expression construct of Claim 68, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a *p53* polypeptide.

99. The viral expression construct of Claim 98, wherein said second therapeutic gene is selected from the group consisting of a Dp gene, p21, p16, p27, E₂F, Rb, APC, DC, NF-1, NF-2, WT-1, MEN-1, MEN-II, BRCA1, VHL,



FCC, MCC, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, Bax, Bcl-X_s and E1A.

100. The viral expression construct of Claim 68, wherein said tumor is located in a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.

101. A viral expression construct when used in a method of inhibiting tumor cell growth in a mammalian subject having a solid tumor wherein said expression construct comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional p53 polypeptide, wherein said polynucleotide is positioned sense to and under the control of said promoter, and wherein said method comprises the step of continuously perfusing a tumor site in said patient with the viral expression construct, the administration resulting in expression of said functional p53 polypeptide in cells of said tumor and inhibition of their growth.

102. The viral expression construct of Claim 101, wherein said tumor is malignant.

103. The viral expression construct of Claim 101, wherein said tumor is a squamous cell carcinoma.

104. The viral expression construct of Claim 101, wherein said tumor is benign.

105. The viral expression construct of Claim 101, wherein the endogenous p53 of said tumor is mutated.



106. The viral expression construct of Claim 101, wherein the endogenous *p53* of said tumor is wild-type.

107. The viral expression construct of Claim 101, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.

108. The viral expression construct of Claim 101, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.

109. The viral expression construct of Claim 108, wherein said adenoviral vector is a replication-deficient adenoviral vector.

110. The viral expression construct of Claim 109, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.

111. The viral expression construct of Claim 101, wherein said promoter is a CMV IE promoter.

112. The viral expression construct of Claim 101, wherein said tumor site is perfused from about one to two hours.

113. The viral expression construct of Claim 101, wherein said subject is a human.

114. The viral expression construct of Claim 101, wherein said tumor site is contacted with said expression vector through a catheter.



115. The viral expression construct of Claim 101, wherein the *p53* polynucleotide is tagged so that expression of a *p53* polypeptide can be detected.

116. The viral expression construct of Claim 115, wherein the tag is a continuous epitope.

117. The viral expression construct of Claim 101, wherein the method further comprises contacting said tumor with a DNA damaging agent.

118. The viral expression construct of Claim 117, wherein said tumor site is contacted with said DNA damaging agent before resection.

119. The viral expression construct of Claim 117, wherein said tumor site is contacted with said DNA damaging agent after resection.

120. The viral expression construct of Claim 117, wherein said tumor site is contacted with said DNA damaging agent before and after resection.

121. The viral expression construct of Claim 117, wherein said DNA damaging agent is a radiotherapeutic agent.

122. The viral expression construct of Claim 121, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.

123. The viral expression construct of Claim 117, wherein said DNA damaging agent is a chemotherapeutic agent.



124. The viral expression construct of Claim 123, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.

125. The viral expression construct of Claim 101, wherein the method further comprises contacting said tumor with a cytokine.

126. The viral expression construct of Claim 125, wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TGF- β , GM-CSF, M-CSF, TNF α , TNF β , LAF, TCGF, BCGF, TRF, BAF, BDG, MP, LIF, OSM, TMF, PDGF, IFN- α , IFN- β , and IFN- γ .

127. The viral expression construct of Claim 101, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a *p53* polypeptide.

128. The viral expression construct of Claim 127, wherein said second therapeutic gene is selected from the group consisting of a Dp gene, p21, p16, p27, E2F, Rb, APC, DC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, FCC, MCC, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, Bax, Bcl-X_s, and E1A.

129. The viral expression construct of Claim 101, wherein said tumor is located into a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.



130. The viral expression construct of Claim 1, wherein said expression vector is administered topically.

131. The viral expression construct of Claim 1, wherein said expression vector is administered intratumorally.

132. The viral expression construct of Claim 1, wherein said expression vector is administered intravenously.


133. The viral expression construct of Claim 1, wherein said expression vector is administered orally.

134. The viral expression construct of Claim 68, wherein said expression vector is administered topically.

135. The viral expression construct of Claim 68, wherein said expression vector is administered intratumorally.

136. The viral expression construct of Claim 68, wherein said expression vector is administered intravenously.

137. The viral expression construct of Claim 68, wherein said expression vector is administered orally.



- 144 -

138. Use of a viral expression construct in the preparation of a medicament for inhibiting growth of a p53-positive tumor cell in a mammalian subject with a solid tumor, wherein said expression construct comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional p53 polypeptide, wherein said polynucleotide is positioned sense to and under the control of said promoter, wherein said expression construct is formulated for direct administration to said tumor *in vivo*, the administration resulting in expression of said functional p53 polypeptide in cells of said tumor and inhibition of tumor cell growth, wherein said tumor comprises cells that express a functional p53 polypeptide.

139. The use of claim 138, wherein said tumor is selected from the group consisting of a carcinoma, a glioma, a sarcoma, and a melanoma.

140. The use of claim 138, wherein said tumor cell is malignant.

141. The use of claim 138, wherein said tumor cell is benign.

142. The use of claim 138, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.

143. The use of claim 138, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.

144. The use of claim 143, wherein said viral vector is a replication-deficient adenoviral vector.

145. The use of claim 144, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.

146. The use of claim 145, wherein said promoter is a CMV IE promoter.

147. The use of claim 138, wherein said subject is a human.



- 145 -

148. The use of claim 144, wherein the expression vector is administered to said tumor at least a second time.

149. The use of claim 148, wherein said tumor is resected following at least a second administration, and an additional administration is effected subsequent to said resection.

150. The use of claim 138, wherein said expression vector is administered in a volume of about 3 ml. to about 10 ml.

151. The use of claim 148, wherein the amount of adenovirus administered in each contacting is between about 10^7 and 10^{12} pfu.

152. The use of claim 138, wherein the expression construct is injected into a natural or artificial body cavity.

153. The use of claim 152, wherein said injection comprises continuous perfusion of said natural or artificial body cavity.

154. The use of claim 152, wherein said contacting is via injection into an artificial body cavity resulting from tumor excision.


155. The use of claim 138, wherein the *p53*-encoding polynucleotide is tagged so that expression of *p53* from said expression vector can be detected.

156. The use of claim 155, wherein the tag is a continuous epitope.

157. The use of claim 138, wherein said tumor is contacted with said expression construct at least twice.

158. The use of claim 157, wherein said multiple injections comprise about 0.1 – 0.5 ml volumes spaced about 1 cm apart.

159. The use of claim 138, wherein the method further comprises contacting said tumor with a DNA damaging agent.



- 146 -

160. The use of claim 159, wherein said DNA damaging agent is a radiotherapeutic agent.

161. The use of claim 160, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.

162. The use of claim 159, wherein said DNA damaging agent is a chemotherapeutic agent.

163. The use of claim 162, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.

164. The use of claim 138, wherein the method further comprises contacting said tumor with a cytokine.


165. The use of claim 138, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a *p53* polypeptide.

166. The use of claim 165, wherein said second therapeutic gene is selected from the group consisting of a *Dp* gene, *p21*, *p16*, *p27*, *E2F*, *Rb*, *APC*, *DC*, *NF-1*, *NF-2*, *WT-1*, *MEN-I*, *MEN-II*, *BRCA1*, *VHL*, *FCC*, *MCC*, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, *Bax*, *Bcl-X_s* and *E1A*.

167. The use of claim 138, wherein said tumor is located into a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.

168. The use of claim 148, wherein said tumor is contacted with said expression construct at least six times within a two week treatment regime.

169. Use of a viral expression construct in the preparation of a medicament for inhibiting microscopic residual tumor cell growth in a mammalian subject, wherein said expression construct comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional *p53* polypeptide, wherein said polynucleotide is



- 147 -

positioned sense to and under the control of said promoter, and wherein said expression construct is formulated for administration to a tumor bed revealed by resection, the administration resulting in expression of said functional p53 polypeptide in said tumor cells and inhibition of their growth.

170. The use of claim 169, wherein said resectable tumor is a squamous cell carcinoma.

171. The use of claim 169, wherein the endogenous *p53* of said resectable tumor is mutated.

172. The use of claim 169, wherein the endogenous *p53* of said resectable tumor is wild-type.

173. The use of claim 169, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.

174. The use of claim 169, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.

175. The use of claim 174, wherein said adenoviral vector is a replication-deficient adenoviral vector.

176. The use of claim 175, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.

177. The use of claim 169, wherein said promoter is a CMV IE promoter.

178. The use of claim 169, wherein the resulting tumor bed is contacted with said expression construct at least twice.

179. The use of claim 169, wherein said expression construct is contacted with said tumor bed prior to closing of the incision.

180. The use of claim 176, wherein said tumor bed is contacted with from about 10^6 to about 10^9 infectious adenoviral particles.



- 148 -

181. The use of claim 178, wherein the method further comprises contacting said tumor with said expression construct prior to resecting said tumor.

182. The use of claim 181, wherein said tumor is injected with said expression construct.

183. The use of claim 182, wherein said tumor is injected with about 10^6 to about 10^9 infectious adenoviral particles.

184. The use of claim 182, wherein said tumor is injected with a total of about 1 ml. to about 10 ml.

185. The use of claim 182, wherein said tumor is injected at least twice.

186. The use of claim 185, wherein each of said injections comprise about 0.1 ml to about 0.5 ml volumes spaced about 1 cm apart.

187. The use of claim 169, wherein the resulting tumor bed is contacted with said expression construct through a catheter.

188. The use of claim 182, wherein said contacting comprises about 10^6 to about 10^9 infectious adenoviral particles.

189. The use of claim 182, wherein said expression construct is contacted with said tumor in total of about 3 ml to about 10 ml.

190. The use of claim 169, wherein the *p53* polynucleotide is tagged so that expression of a *p53* polypeptide can be detected.

191. The use of claim 190, wherein the tag is a continuous epitope.

192. The use of claim 169, wherein the method further comprises contacting said tumor with a DNA damaging agent.

193. The use of claim 192, wherein said DNA damaging agent is contacted before resection.



- 149 -

194. The use of claim 192, wherein said DNA damaging agent is contacted after resection.

195. The use of claim 192, wherein said DNA damaging agent is contacted before and after resection.

196. The use of claim 192, wherein said DNA damaging agent is a radiotherapeutic agent.

197. The use of claim 196, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.

198. The use of claim 196, wherein said DNA damaging agent is a chemotherapeutic agent.


199. The use of claim 198, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.

200. The use of claim 169, wherein the method further comprises contacting said tumor with a cytokine.

201. The use of claim 200, wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TGF- β , GM-CSF, M-CSF, TNF α , TNF β , LAF, TCGF, BCGF, TRF, BAF, BDG, MP, LIF, OSM, TMF, PDGF, IFN- α , IFN- β and IFN- γ .

202. The use of claim 169, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a p53 polypeptide.

203. The use of claim 202, wherein said second therapeutic gene is selected from the group consisting of a Dp gene, p21, p16, p27, E2F, Rb, APC, DC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, FCC, MCC, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, Bax, Bcl-X_s and E1A.



- 150 -

204. The use of claim 169, wherein said tumor is located into a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.

205. Use of a viral expression construct in the preparation of a medicament for inhibiting growth of a tumor cell in a mammalian subject having a solid tumor, wherein said expression construct comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional p53 polypeptide, wherein said polynucleotide is positioned sense to and under the control of said promoter, and wherein said expression construct is formulated for direct administration to a tumor revealed by surgery, the administration resulting in expression of said functional p53 polypeptide in said tumor cells and inhibition of their growth.

206. The use of claim 205, wherein said tumor is malignant.

207. The use of claim 205, wherein said tumor is a squamous cell carcinoma.

208. The use of claim 205, wherein said tumor is benign.

209. The use of claim 205, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.

210. The use of claim 205, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.

211. The use of claim 210, wherein said adenoviral vector is a replication-deficient adenoviral vector.

212. The use of claim 211, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.

213. The use of claim 205, wherein said promoter is a CMV IE promoter.



- 151 -

214. The use of claim 205, wherein said tumor is contacted with said expression construct at least twice.

215. The use of claim 205, wherein said expression construct is contacted with said tumor prior to closing of the incision.

216. The use of claim 211, wherein said tumor is contacted with from about 10^6 to about 10^9 infectious adenoviral particles.

217. The use of claim 205, wherein said tumor is contacted with said expression construct in a total of about 1 ml. to about 10 ml.

218. The use of claim 205, wherein said tumor is injected at least twice.

219. The use of claim 218, wherein each of said injections comprise about 0.1 ml to about 0.5 ml volumes spaced about 1 cm apart.

220. The use of claim 205, wherein said tumor is contacted with said expression construct through a catheter.

221. The use of claim 220, wherein said tumor is contacted with about 10^6 to about 10^9 infectious adenoviral particles.

222. The use of claim 220, wherein said tumor is contacted with an expression construct in a total of about 3 ml to about 10 ml.

223. The use of claim 205, wherein the *p53* polynucleotide is tagged so that expression of a *p53* polypeptide can be detected.

224. The use of claim 223, wherein the tag is a continuous epitope.

225. The use of claim 205, wherein the method further comprises contacting said tumor with a DNA damaging agent.

226. The use of claim 225, wherein said DNA damaging agent is contacted with said tumor before resection.



- 152 -

227. The use of claim 225, wherein said DNA damaging agent is contacted with said tumor after resection.

228. The use of claim 225, wherein said DNA damaging agent is contacted with said tumor before and after resection.

229. The use of claim 225, wherein said DNA damaging agent is a radiotherapeutic agent.

230. The use of claim 229, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.

231. The use of claim 225, wherein said DNA damaging agent is a chemotherapeutic agent.


232. The use of claim 231, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.

233. The use of claim 205, wherein the method further comprises contacting said tumor with a cytokine.

234. The use of claim 233, wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TGF- β , GM-CSF, M-CSF, TNF α , TNF β , LAF, TCGF, BCGF, TRF, BAF, BDG, MP, LIF, OSM, TMF, PDGF, IFN- α , IFN- β and IFN- γ .

235. The use of claim 205, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a *p53* polypeptide.

236. The use of claim 235, wherein said second therapeutic gene is selected from the group consisting of a *Dp* gene, *p21*, *p16*, *p27*, *E2F*, *Rb*, *APC*, *DC*, *NF-1*, *NF-2*, *WT-1*, *MEN-I*, *MEN-II*, *BRCA1*, *VHL*, *FCC*, *MCC*, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, *Bax*, *Bcl-X_s* and *E1A*.



- 153 -

237. The use of claim 205, wherein said tumor is located into a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.

238. Use of a viral expression construct in the preparation of a medicament for inhibiting tumor cell growth in a mammalian subject having a solid tumor, wherein said expression construct comprises a promoter functional in eukaryotic cells and a polynucleotide encoding a functional p53 polypeptide, wherein said polynucleotide is positioned sense to and under the control of said promoter, and wherein said expression construct is formulated for continuously perfusing a tumor site in said subject, the administration resulting in expression of said functional p53 polypeptide in cells of said tumor and inhibition of their growth.

239. The use of claim 238, wherein said tumor is malignant.

240. The use of claim 238, wherein said tumor is a squamous cell carcinoma.

241. The use of claim 238, wherein said tumor is benign.

242. The use of claim 238, wherein the endogenous *p53* of said tumor is mutated.

243. The use of claim 238, wherein the endogenous *p53* of said tumor is wild-type.

244. The use of claim 238, wherein said tumor is a tumor of the lung, skin, prostate, liver, testes, bone, brain, colon, pancreas, head and neck, stomach, ovary, breast or bladder.

245. The use of claim 238, wherein said viral expression construct is selected from the group consisting of a retroviral vector, an adenoviral vector and an adeno-associated viral vector.

246. The use of claim 245, wherein said adenoviral vector is a replication-deficient adenoviral vector.

247. The use of claim 246, wherein said replication-deficient adenoviral vector is lacking at least a portion of the E1-region.



- 154 -

248. The use of claim 238, wherein said promoter is a CMV IE promoter.
249. The use of claim 238, wherein said tumor site is perfused from about one to two hours.
250. The use of claim 238, wherein said subject is a human.
251. The use of claim 238, wherein said tumor site is contacted with said expression vector through a catheter.
252. The use of claim 238, wherein the *p53* polynucleotide is tagged so that expression of a *p53* polypeptide can be detected.
253. The use of claim 252, wherein the tag is a continuous epitope.
254. The use of claim 238, wherein the method further comprises contacting said tumor with a DNA damaging agent.
255. The use of claim 254, wherein said tumor site is contacted with said DNA damaging agent before resection.
256. The use of claim 254, wherein said tumor site is contacted with said DNA damaging agent after resection.
257. The use of claim 254, wherein said tumor site is contacted with said DNA damaging agent before and after resection.
258. The use of claim 254, wherein said DNA damaging agent is a radiotherapeutic agent.
259. The use of claim 258, wherein said radiotherapeutic agent is selected from the group consisting of γ -irradiation, x-irradiation, uv-irradiation and microwaves.
260. The use of claim 254, wherein said DNA damaging agent is a chemotherapeutic agent.



- 155 -

261. The use of claim 260, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, verapamil, doxorubicin, podophyllotoxin and cisplatin.
262. The use of claim 238, wherein the method further comprises contacting said tumor with a cytokine.
263. The use of claim 262, wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TGF- β , GM-CSF, M-CSF, TNF α , TNF β , LAF, TCGF, BCGF, TRF, BAF, BDG, MP, LIF, OSM, TMF, PDGF, IFN- α , IFN- β and IFN- γ .
264. The use of claim 238, wherein the method further comprises contacting said tumor with a second therapeutic gene other than a gene encoding a *p53* polypeptide.
265. The use of claim 264, wherein said second therapeutic gene is selected from the group consisting of a *Dp* gene, *p21*, *p16*, *p27*, *E2F*, *Rb*, *APC*, *DC*, *NF-1*, *NF-2*, *WT-1*, *MEN-I*, *MEN-II*, *BRCA1*, *VHL*, *FCC*, *MCC*, *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun*, *trk*, *ret*, *gsp*, *hst*, *bcl*, *abl*, *Bax*, *Bcl-X_s* and *E1A*.
266. The use of claim 238, wherein said tumor is located into a body cavity selected from the group consisting of the mouth, pharynx, esophagus, larynx, trachea, pleural cavity, peritoneal cavity, bladder interior and colon lumen.
267. The use of claim 138, wherein said expression vector is administered topically.
268. The use of claim 138, wherein said expression vector is administered intratumorally.
269. The use of claim 138, wherein said expression vector is administered intravenously.
270. The use of claim 138, wherein said expression vector is administered orally.
271. The use of claim 205, wherein said expression vector is administered topically.



- 156 -

272. The use of claim 205, wherein said expression vector is administered intratumorally.

273. The use of claim 205, wherein said expression vector is administered intravenously.

274. The use of claim 205, wherein said expression vector is administered orally.

DATED this 13th day of APRIL 2000
Board of Regents, The University of Texas System

By DAVIES COLLISON CAVE

Patent Attorneys for the Applicants



FIG 1




FIG 2A





FIG 2B

FIG 3A




FIG 3B






FIG 3C

FIG 3D

FIG 4




FIG 5A





FIG 5B

FIG 6A




FIG 6B




FIG 7A





FIG 7B